PCT/EP2005 / 001114

RECEIVED
28 FEB 2005
PCT

PA 1253360

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

December 03, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: ***60/543,649***
FILING DATE: ***February 11, 2004***

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

W. MONTGOMERY
Certifying Officer

SUBSTITUTE for Provisional Application for Patent Cover Sheet PTO/SB/16 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a **PROVISIONAL APPLICATION FOR PATENT** under **37 CFR 1.53 (c)**.

DOCKET NUMBER	ITR0073PV

INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
NICOLA	LAMONICA	ROMA, ITALY
ANDREA	FACCIABENE	ROMA, ITALY
LUIGI	AURISICCHIO	ROMA, ITALY

☐ *Additional inventors are being named on the separately numbered sheets attached hereto*

TITLE OF THE INVENTION (500 characters max)

SYNTHETIC GENE ENCODING HUMAN CARCINOEMBRYONIC ANTIGEN AND USES THEREOF

CORRESPONDENCE ADDRESS

Direct all Correspondence to:
Merck & Co., Inc.
Patent Department - RY60-30
P.O. Box 2000
Rahway

☒ Customer Number 000210

STATE	New Jersey	ZIP CODE	07065	COUNTRY	U.S.A.

ENCLOSED APPLICATION PARTS *(check all that apply)*

☒ Specification — *Number of Pages* 43
☒ Drawing(s) — *Number of Sheets* 26
☐ Application Data Sheet. See 37 CFR 1.76
☐ CD(s), Number
☐ Other (specify)

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT *(check one)*

☐ A check or money order is enclosed to cover the filing fees
☒ The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 13-2755

FILING FEE AMOUNT ($) $160.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.
☒ No.
☐ Yes, the name of the U.S. Government agency and the Government contract number are: _____

Respectfully submitted,

SIGNATURE Alysia Finnegan
TYPED or PRINTED NAME Alysia A. Finnegan
TELEPHONE 732-594-2583

Date 02/11/2004
REGISTRATION NO. *(if appropriate)* 48,878

TE: Mail to Mail Stop Provisional Application

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT February 11, 2004
EXPRESS MAIL NO. EL989603786US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

MAILED BY Lou Ickeplis DATE 2/11/04

Duplicate

TITLE OF THE INVENTION
CARCINOEMBRYONIC ANTIGEN FUSIONS AND USES THEREOF

FIELD OF THE INVENTION

The present invention relates generally to the therapy of cancer. More specifically, the present invention relates to polynucleotides encoding fusion proteins wherein the fusion proteins comprise at least a portion of the tumor associated polypeptide carcinoembryonic antigen. The present invention also provides recombinant vectors and hosts comprising said polynucleotides, purified fusion proteins and methods for enhancing an immune response against CEA using the compositions and molecules disclosed herein.

BACKGROUND OF THE INVENTION

The immunoglobulin superfamily (IgSF) consists of numerous genes that code for proteins with diverse functions, one of which is intercellular adhesion. IgSF proteins contain at least one Ig-related domain that is important for maintaining proper intermolecular binding interactions. Because such interactions are necessary to the diverse biological functions of the IgSF members, disruption or aberrant expression of many IgSF adhesion molecules has been correlated with many human diseases.

The carcinoembryonic antigen (CEA) belongs to a subfamily of the Ig superfamily consisting of cell surface glycoproteins. Members of the CEA subfamily are known as CEA-related cell adhesion molecules (CEACAMs). In recent scientific literature, the CEA gene has been renamed CEACAM5, although the nomenclature for the protein remains CEA. Functionally, CEACAMs have been shown to act as both homotypic and heterotypic intercellular adhesion molecules (Benchimol et al., *Cell* 57: 327-334 (1989)). In addition to cell adhesion, CEA inhibits cell death resulting from detachment of cells from the extracellular matrix and can contribute to cellular transformation associated with certain proto-oncogenes such as *Bcl2* and *C-Myc* (*see* Berinstein, *J. Clin Oncol.* 20(8): 2197-2207 (2002)).

Normal expression of CEA has been detected during fetal development and in adult colonic mucosa. CEA overexpression was first detected in human colon tumors over thirty years ago (Gold and Freedman, *J. Exp. Med.* 121:439-462 (1965)) and has since been found in nearly all colorectal tumors. Additionally, CEA overexpression is detectable in a high percentage of adenocarcinomas of the pancreas, breast and lung. Because of the

prevalence of CEA expression in these tumor types, CEA is widely used clinically in the management and prognosis of these cancers.

Sequences coding for human CEA have been cloned and characterized (U.S. Patent No. 5,274,087; U.S. Patent No 5,571,710; and U.S. Patent No 5,843,761. *See also* Beauchemin et al., *Mol. Cell. Biol.* 7:3221-3230 (1987); Zimmerman et al., *Proc. Natl. Acad. Sci. USA* 84:920-924 (1987); Thompson et al. *Proc. Natl. Acad. Sci. USA* 84(9):2965-69 (1987)).

The correlation between CEA expression and metastatic growth has led to its identification as a target for molecular and immunological intervention for colorectal cancer treatment. One therapeutic approach targeting CEA is the use of anti-CEA antibodies (*see* Chester et al., *Cancer Chemother. Pharmacol.* 46 (Suppl): S8-S12 (2000)), while another is to activate the immune system to attack CEA-expressing tumors using CEA-based vaccines (for review, *see* Berinstein, *supra*).

The development and commercialization of many vaccines have been hindered by difficulties associated with obtaining high expression levels of exogenous genes in successfully transformed host organisms. The development of efficacious DNA-based vaccines has also been hindered by an inability to generate an immune response of sufficient magnitude in treated individuals. Therefore, despite the identification of the wild-type nucleotide sequences encoding CEA proteins described above, it would be highly desirable to develop a vaccine which is capable of eliciting an enhanced CEA-specific immune response relative to a wild-type full-length CEA cDNA, when delivered to a mammal. It would also be desirable to develop methods for treating or preventing CEA-associated cancers which utilize nucleic acid molecules or proteins that safely and effectively potentiate a CEA-specific immune response.

SUMMARY OF THE INVENTION

The present invention provides polynucleotides encoding fusion proteins wherein the fusion proteins comprise at least a portion of the tumor associated polypeptide carcinoembryonic antigen, fused to a substantial portion of a bacterial toxin. In preferred embodiments, the CEA portion of the encoded CEA fusion protein is deleted of its C-terminal anchoring domain. In other preferred embodiments, the bacterial toxin is the A or B subunit of the heat labile enterotoxin of *E.coli*, or substantial portion thereof. The present invention also provides recombinant vectors, including but not limited to, adenovirus and plasmid

vectors, comprising said polynucleotides and host cells comprising said recombinant vectors. Also provided herein are purified fusion proteins encoded by invention polynucleotides.

The present invention further provides methods for inhibiting or preventing the development of a cancer in a mammal by eliciting an immune response to the CEA protein by administering a vaccine or pharmaceutical composition comprising the CEA fusions or CEA fusion proteins described herein. In preferred embodiments of the methods herein, the immune response is enhanced relative to the response elicited by a wild-type CEA.

As used throughout the specification and in the appended claims, the singular forms "a," "an," and "the" include the plural reference unless the context clearly dictates otherwise.

As used throughout the specification and appended claims, the following definitions and abbreviations apply:

The term "promoter" refers to a recognition site on a DNA strand to which the RNA polymerase binds. The promoter forms an initiation complex with RNA polymerase to initiate and drive transcriptional activity. The complex can be modified by activating sequences termed "enhancers" or inhibiting sequences termed "silencers".

The term "cassette" refers to a nucleotide or gene sequence that is to be expressed from a vector, for example, the nucleotide or gene sequence encoding the hCEA-LTB fusion. In general, a cassette comprises a gene sequence that can be inserted into a vector, which in some embodiments, provides regulatory sequences for expressing the nucleotide or gene sequence. In other embodiments, the nucleotide or gene sequence provides the regulatory sequences for its expression. In further embodiments, the vector provides some regulatory sequences and the nucleotide or gene sequence provides other regulatory sequences. For example, the vector can provide a promoter for transcribing the nucleotide or gene sequence and the nucleotide or gene sequence provides a transcription termination sequence. The regulatory sequences that can be provided by the vector include, but are not limited to, enhancers, transcription termination sequences, splice acceptor and donor sequences, introns, ribosome binding sequences, and poly(A) addition sequences.

The term "vector" refers to some means by which DNA fragments can be introduced into a host organism or host tissue. There are various types of vectors including plasmid, virus (including adenovirus), bacteriophages and cosmids.

The term "first generation," as used in reference to adenoviral vectors, describes adenoviral vectors that are replication-defective. First generation adenovirus

vectors typically have a deleted or inactivated E1 gene region, and preferably have a deleted or inactivated E3 gene region.

The designation "pV1J/hCEAopt" refers to a plasmid construct, disclosed herein, comprising the CMV immediate-early (IE) promoter with intron A, a full-length codon-optimized human CEA gene, bovine growth hormone-derived polyadenylation and transcriptional termination sequences, and a minimal pUC backbone (see EXAMPLE 2). The designation "pV1J/hCEA" refers to a construct essentially as described above, except the construct comprises a wild-type human CEA gene instead of a codon-optimized human CEA gene.

The designation "pV1J/hCEA-LTB" refers to a plasmid construct, disclosed herein, comprising the CMV immediate-early (IE) promoter with intron A, a human CEA gene devoid of its GPI anchor coding sequence, fused at its C-terminal end to the B subunit of *E. coli* heat labile enterotoxin, bovine growth hormone-derived polyadenylation and transcriptional termination sequences, and a minimal pUC backbone.

The designation "pV1J/hCEAopt-LTB" refers to a construct essentially as described immediately above, except the construct comprises a codon-optimized human CEA gene devoid of its GPI anchor coding sequence instead of the corresponding portion of the wild-type human CEA gene.

The designation "pV1J/hCEAopt-LTBopt" refers to a plasmid construct essentially as described immediately above, except that both the CEA sequences and the LTB sequences are codon-optimized for high level expression in human cells.

The designation "pV1J/rhCEAopt-LTBopt" refers to a construct essentially as described above except that the human codon-optimized CEA gene is replaced with a rhesus monkey CEA gene, codon-optimized for high-level expression in human cells.

The designation "pV1J/hCEA-LTA" refers to a plasmid construct, disclosed herein, comprising the CMV immediate-early (IE) promoter with intron A, a human CEA gene devoid of the GPI anchor coding sequence, fused at its C-terminal end to the A subunit of *E. coli* heat labile enterotoxin, bovine growth hormone-derived polyadenylation and transcriptional termination sequences, and a minimal pUC backbone. Construction of plasmid vectors comprising various CEA-LT fusions is described in EXAMPLE 2.

The designations "Ad5/hCEAopt" and "Ad5/hCEA" refer to two constructs, disclosed herein, which comprise an Ad5 adenoviral genome deleted of the E1 and E3 regions. In the "Ad5/hCEAopt" construct, the E1 region is replaced by a codon-optimized human CEA gene in an E1 parallel orientation under the control of a human CMV promoter

without intron A, followed by a bovine growth hormone polyadenylation signal. The "Ad5/hCEA" construct is essentially as described above, except the E1 region of the Ad5 genome is replaced with a wild-type human CEA sequence. The designation "Ad5/hCEAopt-LTB" refers to an Ad5 construct, essentially as described above, except that the codon-optimized human CEA sequence is devoid of the GPI anchor coding sequence and is fused at its C-terminus to the B subunit of *E. coli* heat labile enterotoxin. Construction of adenovirus vectors comprising various CEA-LT fusions is described in EXAMPLE 3.

The abbreviation "LT" refers generally to the heat labile enterotoxin of *E. coli*. "LT" may refer to the complete enterotoxin, comprising subunits A and B or a substantial portion of subunit A, or a substantial portion of subunit B. The abbreviation "LTA" refers to the A subunit of the heat labile enterotoxin of *E. coli*, or substantial portion thereof, including subunits which are truncated on the C-terminal or N-terminal end but maintain biological activity, as well as subunits that contain internal amino acid insertions, deletions, or substitutions but maintain biological activity. The abbreviation "LTB" refers to the B subunit of the heat labile enterotoxin of *E. coli*, or substantial portion thereof, including subunits which are truncated on the C-terminal or N-terminal end but maintain biological activity, as well as subunits that contain internal amino acid insertions, deletions, or substitutions but maintain biological activity.

As used herein, a "fusion protein" refers to a protein having at least two polypeptides covalently linked in which one polypeptide comes from one protein sequence or domain and the other polypeptide comes from a second protein sequence or domain. The fusion proteins of the present invention comprise a CEA polypeptide or fragment or variant thereof, and a second polypeptide, which comprises a substantial portion of a bacterial toxin, referred to herein as "toxin subunit". The CEA polypeptide, fragment or variant thereof may be a human CEA or CEA homolog from another species. The polypeptides that comprise the fusion protein are preferably linked N-terminus to C-terminus. The CEA polypeptide and the toxin subunit can be fused in any order. In some embodiments of this invention, the C-terminus of the CEA polypeptide is fused to the N-terminus of the toxin subunit, as exemplified in FIGURE 3B. However, fusion proteins in which the toxin subunit is fused to the N-terminus of the CEA polypeptide are also contemplated. The term "CEA fusion protein" is intended to be a general term which refers to a fusion as described above, which comprises a CEA polypeptide or fragment or variant thereof fused to a polypeptide comprising a toxin subunit.

The term "CEA-LT fusion" refers to a nucleic acid sequence in which at least a portion of the CEA gene is fused to a substantial portion of either the LTA or the LTB subunit of *E. coli* heat labile enterotoxin. The term "CEA-LT fusion protein" refers to a polypeptide encoded by a CEA-LT fusion as described. The terms "CEA-LT fusion" and "CEA-LT fusion protein" are also understood to refer to fragments thereof, homologs thereof, and functional equivalents thereof (collectively referred to as "variants"), such as those in which one or more amino acids is inserted, deleted or replaced by other amino acid(s). The CEA-LT fusions of the present invention, upon administration to a mammal such as a human being, can stimulate an immune response by helper T cells or cytotoxic T cells, or stimulate the production of antibodies at least as well as a "wild-type" CEA sequence. In preferred embodiments of the invention, the CEA-LT fusion can enhance the immune response as compared to a wild-type CEA.

The abbreviation "AD" refers to the anchoring domain of a CEA gene or protein. The anchoring domain of the wild-type human CEA is located from about amino acid 679 to about amino acid 702 of SEQ ID NO:20.

The term "treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in which the disorder is to be prevented.

A "disorder" is any condition that would benefit from treatment with the molecules of the present invention, including the nucleic acid molecules described herein and the fusion proteins that are encoded by said nucleic acid molecules. Encompassed by the term "disorder" are chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question. The molecules of the present invention are intended for use as treatments for disorders or conditions characterized by aberrant cell proliferation, including, but not limited to, breast cancer, colorectal cancer, and lung cancer.

The term "effective amount" means sufficient vaccine composition is introduced to produce the adequate levels of the polypeptide, so that an immune response results. One skilled in the art recognizes that this level may vary.

A "conservative amino acid substitution" refers to the replacement of one amino acid residue by another, chemically similar, amino acid residue. Examples of such conservative substitutions are: substitution of one hydrophobic residue (isoleucine, leucine, valine, or methionine) for another; substitution of one polar residue for another polar residue of the same charge (e.g., arginine for lysine; glutamic acid for aspartic acid).

"hCEA" and "hCEAopt" refer to a human carcinoembryonic antigen and a human codon-optimized carcinoembryonic antigen, respectively.

"Substantially similar" means that a given nucleic acid or amino acid sequence shares at least 75%, preferably 85%, more preferably 90%, and even more preferably 95% identity with a reference sequence. In the present invention, the reference sequence can be relevant portions of the wild-type human CEA nucleotide or amino acid sequence, or the wild-type nucleotide or amino acid sequence of a bacterial toxin or subunit thereof, such as the LTB or LTA subunits of the *E.coli* heat labile enterotoxin, as dictated by the context of the text. The reference sequence may also be, for example, the wild-type rhesus monkey CEA sequence. Thus, a CEA protein sequence that is "substantially similar" to the wild-type human CEA protein or fragment thereof will share at least 75% identity with the relevant fragment of the wild-type human CEA, along the length of the fragment, preferably 85% identity, more preferably 90% identity and even more preferably 95% identity. Whether a given CEA, LTB, or LTA protein or nucleotide sequence is "substantially similar" to a reference sequence can be determined for example, by comparing sequence information using sequence analysis software such as the GAP computer program, version 6.0, available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilizes the alignment method of Needleman and Wunsch (*J. Mol. Biol.* 48:443, 1970), as revised by Smith and Waterman (*Adv. Appl. Math.* 2:482, 1981).

A "substantial portion" of a gene, variant, fragment, or subunit thereof, means a portion of at least 50%, preferably 75%, more preferably 90%, and even more preferably 95% of a reference sequence.

A "gene" refers to a nucleic acid molecule whose nucleotide sequence codes for a polypeptide molecule. Genes may be uninterrupted sequences of nucleotides or they may include such intervening segments as introns, promoter regions, splicing sites and repetitive sequences. A gene can be either RNA or DNA. A preferred gene is one that encodes the invention peptide.

The term "nucleic acid" or "nucleic acid molecule" is intended for ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), probes, oligonucleotides, fragment or portions thereof, and primers. DNA can be either complementary DNA (cDNA) or genomic DNA, e.g. a gene encoding a CEA fusion protein.

"Wild-type CEA" or "wild-type protein" or "wt protein" refers to a protein comprising a naturally occurring sequence of amino acids or variant thereof. The amino acid sequence of wild-type human CEA is shown in FIGURE 7E (SEQ ID NO:20). The amino

acid sequence of the wild-type rhesus monkey CEA was previously described (U.S.S.N. 60/447,203, see FIGURES 7A-7B).

"Wild-type CEA gene" refers to a gene comprising a sequence of nucleotides that encodes a naturally occurring CEA protein, including proteins of human origin or proteins obtained from another organism, including, but not limited to, other mammals such as rat, mouse and rhesus monkey. The nucleotide sequence of the human CEA gene is available in the art (*supra*). *See also* Beauchemin et al., *Mol. Cell. Biol.* 7:3221-3230 (1987); Zimmerman et al., *Proc. Natl. Acad. Sci. USA* 84:920-924 (1987); and Thompson et al. *Proc. Natl. Acad. Sci. USA* 84(9):2965-69 (1987). The nucleotide sequence of the wild-type rhesus monkey gene is shown in FIGURES 7C-7D.

The term "mammalian" refers to any mammal, including a human being.

The abbreviation "Ag" refers to an antigen.

The abbreviations "Ab" and "mAb" refer to an antibody and a monoclonal antibody, respectively.

The abbreviation "ORF" refers to the open reading frame of a gene.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows a schematic representation of the vectors developed in this study. The essential features of the plasmid and Ad vectors encoding the CEA-LTA and CEA-LTB fusions are indicated. The inverted terminal repeats (ITR) of the Ad5 genome are also shown.

FIGURE 2 shows the nucleotide (SEQ ID NO:7, Panel A) and amino acid sequence (SEQ ID NO:8, Panel B) of an exemplary hCEA-LTA fusion. The LTA nucleotide sequence is shown in bold.

FIGURE 3 shows the nucleotide (SEQ ID NO:9, Panel A) and amino acid sequence (SEQ ID NO:10, Panel B) of an exemplary hCEA-LTB fusion. The LTB nucleotide sequence is shown in bold.

FIGURE 4 shows the nucleotide sequence of an exemplary hCEAopt-LTB fusion (SEQ ID NO:11). The LTB nucleotide sequence is shown in bold.

FIGURE 5 shows the nucleotide (SEQ ID NO:12, Panel A) and amino acid sequence (SEQ ID NO:13, Panel B) of an exemplary fully optimized hCEA-LTB fusion, designated herein hCEAopt-LTBopt. The LTB nucleotide and amino acid sequences are shown in bold. Junction sequences, created by the cloning strategy employed to fuse the CEA and LTB sequences are underlined.

FIGURE 6 shows the nucleotide (SEQ ID NO:14, Panel A) and amino acid sequence (SEQ ID NO:15, Panel B) of a fully optimized rhesus monkey CEA-LTB fusion, designated herein rhCEAoptLTBopt. LTB nucleotide and amino acid sequences are shown in bold. Junction sequences, created by the cloning strategy employed to fuse the CEA and LTB sequences, are underlined.

FIGURE 7 shows nucleotide sequences of wild-type genes encoding rhesus monkey CEA (Panels A and B, SEQ ID NOs:16 and 17) and the amino acid sequences of the corresponding proteins (Panels C and D, SEQ ID NOs:18 and 19), as previously described (U.S.S.N. 60/447,203). Panel E shows the amino acid sequence of wild-type human CEA (SEQ ID NO:20), which was previously described (*see, e.g.,* U.S. Patent No. 5,274,087).

FIGURE 8 shows a comparison of CEA expression efficiency in cells transfected with different CEA constructs. Panel A depicts the expression efficiencies of HeLa cells transfected with 3 μg of plasmids carrying the wild type sequences of hCEA, hCEA-LTA, and hCEA-LTB, in conjunction with 0.2 μg of plasmid pV1J/mEPO as tracer. Panel B shows results from a similar transfection experiment using pV1J/hCEAopt and pV1J/hCEAopt-LTB. Expression efficiency was determined three days post-transfection by measuring the amount of CEA protein present in cell extracts and by normalizing this value for EPO expression. Data shown relates to the average CEA expression values of two independent transfections.

FIGURE 9 shows a comparison of the expression efficiency of different Adenovirus recombinant vectors expressing CEA. HeLa cells were infected at an moi of 100 and 1000 with Ad/hCEAopt and Ad/hCEAopt-LTB. Expression efficiency was determined by measuring three days post infection the amount of CEA protein released in cell extracts. Data shown reflects the average CEA expression values of two independent infections.

FIGURE 10 shows an analysis of the cell mediated immune response elicited by different plasmid vectors encoding human CEA. Three groups of C57BL/6 mice were electroinjected intramuscularly with 50μg of the indicated plasmid (CEA, CEA-LTA fusion or CEA-LTB fusion) at 0 and 3 weeks. A fourth group of mice was immunized with a mixture of 25 μg of pV1J/hCEA-LTA and 25 μg of pV1J/hCEA-LTB. Panel A. Two weeks post boost, the number of IFNγ-secreting T cells specific for CEA was determined by ELISPOT assay on splenocytes from individual mice (empty circles) using peptide pools that encompass the entire protein. Geometric mean values (filled diamonds) are also indicated. Panel B depicts results of IFNγ intracellular staining of pooled splenocytes from immunized

mice using peptide pool D. The nonspecific IFNγ production (DMSO) is shown for each group.

FIGURE 11 shows antibody titers from mice immunized with plasmid DNA vectors encoding CEA. Individual titers against purified human CEA protein were measured by ELISA on serum from individual mice immunized with plasmids pV1J/hCEA, pV1J/hCEA-LTA and pV1J/hCEA-LTB. Average values are also shown (filled diamonds).

FIGURE 12 shows an analysis of the cell mediated immune response elicited by different plasmid vectors encoding CEA. Groups of 4 BALB/c mice were electroinjected with the indicated plasmid as indicated above (FIGURE 4). Two weeks after the last injection, the number of IFNγ secreting T cells specific for CEA was determined by ELISPOT assay on splenocytes from individual mice (empty circles) using peptide pools that encompass the entire protein. Average values (filled diamonds) are also indicated.

FIGURE 13 shows an analysis of the CEA-specific $CD8^+$ T cell response elicited by different plasmid vectors encoding CEA. C57/DR4 mice were electroinjected with the indicated plasmid as described above (see FIGURE 4). Two weeks after the last injection, IFNγ intracellular staining of pooled splenocytes from immunized mice was performed using peptide pool D. The nonspecific IFNγ production (DMSO) is shown for each group.

FIGURE 14 shows an analysis of CEA-specific $CD8^+$ T cell response elicited by different plasmid vectors encoding CEA. HHD mice were electroinjected with the indicated plasmid as described above (see FIGURE 4). Two weeks after the last injection, IFNγ intracellular staining of pooled splenocytes from immunized mice was performed using peptide pools B and D. The nonspecific IFNγ production (DMSO) is shown for each group.

FIGURE 15 shows the cell-mediated and humoral immune response of CEA transgenic mice (N=9) immunized with 5 weekly electroinjections of the indicated plasmids. A total amount of 50 μg of plasmid DNA was injected i.m. at each vaccination. Panel A. Two weeks after the last injection, the number of IFNγ secreting T cells specific for CEA was determined by intracellular staining on splenocytes from individual mice (circles) using peptide pool D. Geometric mean values (triangles) are also indicated. Panel B. Individual titers against purified human CEA protein were measured by ELISA on each serum from mice immunized with plasmids pV1J/hCEAopt and pV1J/hCEA-LTB. Geometric mean values are also shown (filled diamonds). These data indicate that the CEA-LTB fusion breaks tolerance to CEA in transgenic mice.

FIGURE 16 shows an analysis of the CEA-specific $CD8^+$ T cell response elicited by different Adenovirus vectors encoding CEA. CEA transgenic mice were immunized with different doses of Ad/hCEAopt and Ad/CEAopt-LTB at 0 and 2 weeks. Two weeks after the last injection, IFNγ intracellular staining of PBMC from each immunized mouse was performed using peptide pool D (filled circles). Geometric mean values are also shown (filled diamonds). The nonspecific IFNγ production (DMSO) of each injected group was less or equal to 0.01%.

FIGURE 17 shows the results of tumor protection studies of immunized CEA transgenic mice challenged with MC38-CEA cells. Groups of 10 CEA transgenic mice were immunized with 5 weekly electroinjections of the indicated plasmid DNA (50 μg/injection). Two weeks after the last DNA injection, mice were boosted with a single injection of $1x10^{10}$ vp of the corresponding Ad vector. Fourteen days after the Adenovirus boost, mice were challenged with a subcutaneous injection of $5x10^5$ MC38-CEA cells. Panel A shows the percentage of tumor free mice at the indicated timepoint. Panel B reports the average tumor volumes of each immunized group. These data demonstrate that immunization of CEA transgenic mice with CEA-LTB protects mice from tumor development

DETAILED DESCRIPTION OF THE INVENTION

Carcinoembryonic antigen (CEA) is commonly associated with the development of adenocarcinomas. The present invention relates to compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with the carcinoma or its development. Association of aberrant CEA expression with a carcinoma does not require that the CEA protein be expressed in tumor tissue at all timepoints of its development, as abnormal CEA expression may be present at tumor initiation and not be detectable late into tumor progression or vice-versa.

To this end, the present invention provides polynucleotides, vectors, host cells, and encoded proteins comprising a CEA sequence or variant thereof for use in vaccines and pharmaceutical compositions for the treatment and/or prevention of a cancer. The polynucleotides of the present invention comprise a nucleotide sequence encoding a CEA protein or variant thereof, fused to a nucleotide sequence encoding at least a subunit of a bacterial enterotoxin or substantial portion thereof, which can effectively adjuvant an immune response to the associated CEA.

The CEA nucleotide sequences of the present invention can be of human origin or can be a CEA homolog from another species. The wild-type human CEA nucleotide sequence has been reported (*see, e.g.,* U.S. Patent No. 5,274,087; U.S. Patent No 5,571,710; and U.S. Patent No 5,843,761). The rhesus monkey CEA sequence was recently described (U.S.S.N. 60/447,203). The CEA portion of the CEA fusion may be full-length, or any variant sufficient to elicit a CEA-specific immune response in a mammal. CEA variants of the present invention include, but are not limited to sequences that are C- or N-terminally truncated, sequences with conservative substitutions, and sequences with internal deletions or insertions.

In preferred embodiments of the present invention, the CEA portion of the CEA fusion is human CEA or a functional equivalent thereof. In other preferred embodiments, the CEA portion is a rhesus monkey CEA, or functional equivalent thereof.

Accordingly, the present invention relates to a synthetic polynucleotide comprising a sequence of nucleotides encoding a CEA fusion protein, said fusion protein comprising a CEA protein or a biologically active fragment or mutant form of a CEA protein fused to a bacterial enterotoxin or subunit thereof, which can effectively enhance the immune response to the CEA protein. Said mutant forms of the CEA protein include, but are not limited to: conservative amino acid substitutions, amino-terminal truncations, carboxy-terminal truncations, deletions, or additions. Any such biologically active fragment and/or mutant will encode either a protein or protein fragment which at least substantially mimics the immunological properties of the CEA protein as set forth in SEQ ID NO:20. The synthetic polynucleotides of the present invention encode mRNA molecules that express a functional CEA fusion protein so as to be useful in the development of a therapeutic or prophylactic cancer vaccine.

In preferred embodiments, the CEA portion of the encoded CEA fusion protein is deleted of its C-terminal anchoring domain (AD) , which is located from about amino acid 679 to about amino acid 702 of the human full-length CEA (SEQ ID NO:20). While not being bound by theory, deletion of the anchoring domain increases secretion of the CEA fusion protein, thereby enhancing cross priming of the CEA-LTB immune response.

The bacterial toxin portion of the CEA fusion proteins of the present invention can be any bacterial enterotoxin capable of stimulating or enhancing the immune response to the associated CEA protein. One of skill in the art can choose a toxin sufficient for use as an adjuvant in the production of a vaccine for treatment or prophylaxis of a CEA-associated cancer. Examples of toxins for use as adjuvants in the methods of the present invention

include, but are not limited to: cholera toxin (CT) from *Vibrio cholerae*, heat labile enterotoxin of *E.coli* (LT), *Pseudomonas aeruginosa* exotoxin A, pertussis toxin of *Bordatella pertussis*, Shiga toxin B subunit, and tetanus toxin, fragment C.. In preferred embodiments of the present invention, the adjuvant portion of the CEA fusion is a subunit of LT, which has been shown to strongly potentiate the immunogenicity of codelivered antigens (See, e.g. Simmons et al. *Scand. J. Immunol.* 53:218-26 (2001)). In further preferred embodiments, the adjuvant portion of the CEA fusion is a substantial portion of an LTB subunit.

A CEA fusion comprising a truncated human CEA fused to a single epitope of tetanus toxin (Q830 – L844) has been described (Lund et al. *Cancer Gene Therapy* 10: 365-376 (2003)). Unlike this single-epitope fusion, the CEA fusions of the present invention comprise a substantial portion of a bacterial toxin or subunit thereof, which is capable of enhancing the immunogenicity of a CEA protein or variant thereof. A substantial portion of a bacterial toxin to be used for the compositions and methods described herein does not include portions that are less than 50% of a full-length toxin subunit. The strategy used herein, which utilizes full-length toxin subunits or substantial portions thereof, was employed to ensure a greater immune response to the fused CEA sequence. While not being bound by theory, it is believed that if the bacterial toxin chosen as adjuvant comprises greater than one helper epitope, limiting the toxin sequence of the fusion protein to a single epitope would arguably lead to a reduced effect on the immunogenicity of the target protein. Additionally, it is believed that if the toxin-mediated enhancement of the immune response is dependent on the interaction of the toxin with specific cell receptors and not based on a universal epitope, then the receptor interaction could depend on a specific structural configuration that would require a substantial portion of the toxin to exert an adjuvant effect. In such a case, a short toxin sequence comprising a single epitope would be insufficient in mediating an increase of the immune response.

Also contemplated for use in the present invention are nucleotide sequences encoding bacterial toxin variants or mutants including but not necessarily limited to: nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations. In some cases, it may be advantageous to add specific point mutations to the nucleotide sequence encoding the bacterial toxin or subunit to reduce or eliminate toxicity of the encoded protein. In preferred embodiments of the present invention the LT subunit fused to the CEA sequence is truncated of its signal sequence. While not being bound

by theory, deletion of the toxin signal sequence, e.g. the LTB signal sequence, ensures that posttranslational processing of the CEA fusion is driven by the CEA signal sequence.

The bacterial toxin, subunit, or substantial portion thereof may be fused to the amino terminus or the carboxy terminus of the CEA sequence. Further, the toxin sequence and the CEA sequence can be fused N-terminus to N-terminus, C-terminus to C-terminus, C-terminus to N-terminus or N-terminus to N-terminus. In preferred embodiments of the present invention, the C-terminus of the CEA polypeptide is fused to the N-terminus of the toxin subunit.

The present invention relates to a synthetic nucleic acid molecule (polynucleotide) comprising a sequence of nucleotides which encodes mRNA that expresses a novel CEA fusion protein; for example, nucleotide sequences encoding the fusion proteins as set forth in SEQ ID NOs:8, 10, 13 and 15. The nucleic acid molecules of the present invention are substantially free from other nucleic acids.

The present invention also relates to recombinant vectors and recombinant host cells, both prokaryotic and eukaryotic, which contain the nucleic acid molecules disclosed throughout this specification. The synthetic DNA molecules, associated vectors, and hosts of the present invention are useful for the development of a cancer vaccine.

Exemplary nucleic acid molecules of the present invention comprise a nucleotide sequence selected from the group consisting of: SEQ ID NOs: 7, 9, 11, 12, and 14, as shown in FIGUREs 2-6, which encode exemplary CEA-LTA and CEA-LTB fusion proteins of the present invention.

The present invention also includes biologically active fragments or mutants of SEQ ID NOs: 7, 9, 11, 12, and 14, which encode mRNA expressing exemplary CEA fusion proteins. Any such biologically active fragment and/or mutant will encode either a protein or protein fragment which at least substantially mimics the pharmacological properties of the hCEA protein, including but not limited to the hCEA protein as set forth in SEQ ID NO:20. Any such polynucleotide includes but is not necessarily limited to: nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations. The mutations of the present invention encode mRNA molecules that express a functional CEA fusion protein in a eukaryotic cell so as to be useful in cancer vaccine development.

Also included within the scope of this invention are mutations in the DNA sequence that do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in the functionality of the polypeptide.

As stated above, the present invention further relates to recombinant vectors that comprise the nucleic acid molecules disclosed throughout this specification. These vectors may be comprised of DNA or RNA. For most cloning purposes, DNA vectors are preferred. Typical vectors include plasmids, modified viruses, baculovirus, bacteriophage, cosmids, yeast artificial chromosomes, and other forms of episomal or integrated DNA that can encode a CEA fusion protein. It is well within the purview of the skilled artisan to determine an appropriate vector for a particular gene transfer or other use.

Also provided by the present invention are purified CEA fusion proteins encoded by the nucleic acids disclosed throughout this specification. In exemplary embodiments of this aspect of the invention, the CEA fusion protein comprises a sequence of amino acids selected from the group consisting of: SEQ ID NOs: 8, 10, 13, and 15.

Included in the present invention are DNA sequences that hybridize to SEQ ID NOs: 8, 10, 13, or 15 under stringent conditions. By way of example, and not limitation, a procedure using conditions of high stringency is as follows. Prehybridization of filters containing DNA is carried out for about 2 hours to overnight at about 65°C in buffer composed of 6x SSC, 5x Denhardt's solution, and 100 μg/ml denatured salmon sperm DNA. Filters are hybridized for about 12 to 48 hrs at 65°C in prehybridization mixture containing 100 μg/ml denatured salmon sperm DNA and 5-20 x 10^6 cpm of ^{32}P-labeled probe. Washing of filters is done at 37°C for about 1 hour in a solution containing 2x SSC, 0.1% SDS. This is followed by a wash in 0.1x SSC, 0.1% SDS at 50°C for 45 minutes before autoradiography. Other procedures using conditions of high stringency would include either a hybridization step carried out in 5x SSC, 5x Denhardt's solution, 50% formamide at about 42°C for about 12 to 48 hours or a washing step carried out in 0.2x SSPE, 0.2% SDS at about 65°C for about 30 to 60 minutes. Reagents mentioned in the foregoing procedures for carrying out high stringency hybridization are well known in the art. Details of the composition of these reagents can be found in Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd Edition; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, (1989) or Sambrook and Russell, Molecular Cloning: A Laboratory Manual, 3rd Edition. Cold Spring Harbor Laboratory Press, Plainview, NY (2001). In addition to the foregoing, other conditions of high stringency which may be used are also well known in the art.

An expression vector containing a CEA fusion protein-encoding nucleic acid molecule may be used for high-level expression of CEA fusion protein in a recombinant host cell. Expression vectors may include, but are not limited to, cloning vectors, modified

cloning vectors, specifically designed plasmids or viruses. Also, a variety of bacterial expression vectors may be used to express recombinant CEA fusion sequences in bacterial cells if desired. In addition, a variety of fungal cell expression vectors may be used to express recombinant CEA fusion sequences in fungal cells. Further, a variety of insect cell expression vectors may be used to express recombinant protein in insect cells.

The present invention also relates to host cells transformed or transfected with vectors comprising the nucleic acid molecules of the present invention. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of bovine, porcine, monkey and rodent origin; and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Such recombinant host cells can be cultured under suitable conditions to produce a CEA fusion protein or a biologically equivalent form. In a preferred embodiment of the present invention, the host cell is human. As defined herein, the term "host cell" is not intended to include a host cell in the body of a transgenic human being, human fetus, or human embryos.

As noted above, an expression vector containing DNA encoding a CEA fusion protein may be used for expression of CEA fusion protein in a recombinant host cell. Therefore, another aspect of this invention is a process for expressing a CEA fusion protein in a recombinant host cell, comprising: (a) introducing a vector comprising a nucleic acid comprising a sequence of nucleotides that encodes a CEA fusion protein into a suitable human host cell, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof, and wherein the fusion protein is capable of producing an immune response in a mammal; and, (b) culturing the host cell under conditions which allow expression of said CEA fusion protein.

This invention also provides a process for expressing a CEA-LT fusion protein in a recombinant host cell, comprising: (a) introducing a vector comprising a nucleic acid comprising a sequence of nucleotides that encodes a CEA-LT fusion protein into a suitable human host cell, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a subunit of a heat labile enterotoxin of *E. Coli* (LT), and wherein the fusion protein is capable of producing an immune response in a mammal; and, (b) culturing the host cell under conditions which allow expression of said CEA-LT fusion protein.

In preferred embodiments of the process for expressing a CEA-LT fusion protein described above, the LT subunit is a substantial portion of LTB, wherein the LTB

sequence is deleted of its signal sequence. In other embodiments, the LT subunit is LTA, or a substantial portion thereof.

Following expression of a CEA fusion in a host cell, CEA fusion protein may be recovered to provide CEA fusion protein in active form. Several protein purification procedures are available and suitable for use. Recombinant protein may be purified from cell lysates and extracts by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography. In addition, recombinant CEA fusion protein can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for a CEA protein, or polypeptide fragments of a CEA protein.

The nucleic acid molecules comprising CEA fusions and the encoded fusion proteins of this invention were designed to enhance the CEA-specific immune response, relative to full-length cDNA encoding CEA, for use in vaccine development. To further enhance the immunogenic properties of the CEA fusion sequences of the present invention, in some embodiments described herein, the polynucleotides encoding CEA fusion proteins comprise optimized codons for further high level expression in a host cell, as described below. In these embodiments, at least a portion of the codons of the CEA fusions are designed so as to use the codons preferred by the projected host cell, which in preferred embodiments is a human cell. The optimized CEA fusions may be used for the development of recombinant adenovirus or plasmid-based DNA vaccines, which provide effective immunoprophylaxis against CEA-associated cancer through neutralizing antibody and cell-mediated immunity. The synthetic molecules may be used as an immunogenic composition. This invention provides codon-optimized CEA fusion polynucleotides which, when directly introduced into a vertebrate *in vivo*, including mammals such as primates and humans, induce the expression of encoded proteins within the animal.

As stated above, in some embodiments of the present invention, the synthetic molecules comprise a sequence of nucleotides, wherein some of the nucleotides have been altered so as to use the codons preferred by a human cell, thus allowing for high-level fusion protein expression in a human host cell. The synthetic molecules may be used as a source of a CEA fusion protein, for example, CEA-LTB fusion protein, which may be used in a cancer vaccine to provide effective immunoprophylaxis against CEA-associated carcinomas through

neutralizing antibody and cell-mediated immunity. The nucleic acid molecules disclosed herein may also serve as the basis for a DNA-based cancer vaccine.

A "triplet" codon of four possible nucleotide bases can exist in over 60 variant forms. Because these codons provide the message for only 20 different amino acids (as well as transcription initiation and termination), some amino acids can be coded for by more than one codon, a phenomenon known as codon redundancy. For reasons not completely understood, alternative codons are not uniformly present in the endogenous DNA of differing types of cells. Indeed, there appears to exist a variable natural hierarchy or "preference" for certain codons in certain types of cells. As one example, the amino acid leucine is specified by any of six DNA codons including CTA, CTC, CTG, CTT, TTA, and TTG. Exhaustive analysis of genome codon frequencies for microorganisms has revealed endogenous DNA of *E. coli* most commonly contains the CTG leucine-specifying codon, while the DNA of yeasts and slime molds most commonly includes a TTA leucine-specifying codon. In view of this hierarchy, it is generally believed that the likelihood of obtaining high levels of expression of a leucine-rich polypeptide by an *E. coli* host will depend to some extent on the frequency of codon use. For example, it is likely that a gene rich in TTA codons will be poorly expressed in *E. coli*, whereas a CTG rich gene will probably be highly expressed in this host. Similarly, a preferred codon for expression of a leucine-rich polypeptide in yeast host cells would be TTA.

The implications of codon preference phenomena on recombinant DNA techniques are manifest, and the phenomenon may serve to explain many prior failures to achieve high expression levels of exogenous genes in successfully transformed host organisms--a less "preferred" codon may be repeatedly present in the inserted gene and the host cell machinery for expression may not operate as efficiently. This phenomenon suggests that synthetic genes which have been designed to include a projected host cell's preferred codons provide an optimal form of foreign genetic material for practice of recombinant DNA techniques. Thus, one aspect of this invention is a CEA fusion gene that is codon-optimized for expression in a human cell. In a preferred embodiment of this invention, it has been found that the use of alternative codons encoding the same protein sequence may remove the constraints on expression of exogenous CEA fusion protein in human cells.

In accordance with some embodiments of the present invention, the nucleic acid molecules which encode the CEA fusion proteins are converted to a polynucleotide sequence having an identical translated sequence but with alternative codon usage as described by Lathe, "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence

Data: Theoretical and Practical Considerations" *J. Molec. Biol.* 183:1-12 (1985), which is hereby incorporated by reference. The methodology generally consists of identifying codons in the wild-type sequence that are not commonly associated with highly expressed human genes and replacing them with optimal codons for high expression in human cells. The new gene sequence is then inspected for undesired sequences generated by these codon replacements (e.g., "ATTTA" sequences, inadvertent creation of intron splice recognition sites, unwanted restriction enzyme sites, etc.). Undesirable sequences are eliminated by substitution of the existing codons with different codons coding for the same amino acid. The synthetic gene segments are then tested for improved expression.

The methods described above were used to create synthetic gene sequences which encode CEA-LT fusion proteins, resulting in a gene comprising codons optimized for high level expression. While the above procedure provides a summary of our methodology for designing codon-optimized genes for use in cancer vaccines, it is understood by one skilled in the art that similar vaccine efficacy or increased expression of genes may be achieved by minor variations in the procedure or by minor variations in the sequence.

One of skill in the art will also recognize that additional nucleic acid molecules may be constructed that provide for high levels of CEA-LT fusion expression in human cells, wherein only a portion of the codons of the DNA molecules are codon-optimized. For example, in some embodiments of the present invention, codons comprising the CEA portion of the CEA-LT fusion are optimized for high-level expression in human cells, and codons comprising the LT portion of the CEA-LT fusion are substantially similar to the wild-type LTA or LTB subunits of the LT gene. In other embodiments of the present invention, codons comprising the LT portion of the CEA-LT fusion are optimized for high-level expression in human cells, and codons comprising the CEA portion of the CEA-LT fusion are substantially similar to a wild-type CEA gene. In still other embodiments of the present invention, both the CEA and LT portions of the CEA-LT fusion are codon-optimized for high-level expression in human cells. CEA-LT fusions in which only a subset of codons are optimized within the CEA and/or the LT portion of the CEA-LT fusion are also contemplated by this invention.

The nucleic acids of the present invention may be assembled into an expression cassette which comprises sequences designed to provide for efficient expression of the protein in a human cell. The cassette preferably contains CEA fusion protein-encoding gene, with related transcriptional and translations control sequences operatively linked to it, such as a promoter, and termination sequences. In a preferred embodiment, the promoter is

the cytomegalovirus promoter without the intron A sequence (CMV), although those skilled in the art will recognize that any of a number of other known promoters such as the strong immunoglobulin, or other eukaryotic gene promoters may be used. A preferred transcriptional terminator is the bovine growth hormone terminator, although other known transcriptional terminators may also be used. The combination of CMV-BGH terminator is particularly preferred.

In accordance with this invention, the CEA fusion expression cassette is inserted into a vector. The vector is preferably an adenoviral or plasmid vector, although linear DNA linked to a promoter, or other vectors, such as adeno-associated virus or a modified vaccinia virus, retroviral or lentiviral vector may also be used.

If the vector chosen is an adenovirus, it is preferred that the vector be a so-called first-generation adenoviral vector. These adenoviral vectors are characterized by having a non-functional E1 gene region, and preferably a deleted adenoviral E1 gene region. In some embodiments, the expression cassette is inserted in the position where the adenoviral E1 gene is normally located. In addition, these vectors optionally have a non-functional or deleted E3 region. It is preferred that the adenovirus genome used be deleted of both the E1 and E3 regions (ΔE1ΔE3). The adenoviruses can be multiplied in known cell lines which express the viral E1 gene, such as 293 cells, or PERC.6 cells, or in cell lines derived from 293 or PERC.6 cell which are transiently or stablily transformed to express an extra protein. For examples, when using constructs that have a controlled gene expression, such as a tetracycline regulatable promoter system, the cell line may express components involved in the regulatory system. One example of such a cell line is T-Rex-293; others are known in the art.

For convenience in manipulating the adenoviral vector, the adenovirus may be in a shuttle plasmid form. This invention is also directed to a shuttle plasmid vector which comprises a plasmid portion and an adenovirus portion, the adenovirus portion comprising an adenoviral genome which has a deleted E1 and optional E3 deletion, and has an inserted expression cassette comprising a CEA fusion protein encoding nucleotide sequence. In preferred embodiments, there is a restriction site flanking the adenoviral portion of the plasmid so that the adenoviral vector can easily be removed. The shuttle plasmid may be replicated in prokaryotic cells or eukaryotic cells.

In a preferred embodiment of the invention, the expression cassette is inserted into the pMRKAd5-HV0 adenovirus plasmid (*See* Emini et al., WO 02/22080, which is hereby incorporated by reference). This plasmid comprises an Ad5 adenoviral genome

deleted of the E1 and E3 regions. The design of the pMRKAd5-HV0 plasmid was improved over prior adenovectors by extending the 5' cis-acting packaging region further into the E1 gene to incorporate elements found to be important in optimizing viral packaging, resulting in enhanced virus amplification. Advantageously, this enhanced adenoviral vector is capable of maintaining genetic stability following high passage propagation.

Standard techniques of molecular biology for preparing and purifying DNA constructs enable the preparation of the adenoviruses, shuttle plasmids, and DNA immunogens of this invention.

It has been determined in accordance with the present invention that the CEA fusion protein-encoding molecules described herein (e.g. SEQ ID NO:12), which comprise a substantial portion of the LTA or LTB subunits of *E.coli* heat labile enterotoxin, are expressed with equivalent efficiency compared to the corresponding wild type CEA sequence (*See* EXAMPLE 4). It has also been shown herein that plasmids pV1J/hCEA-LTA and pV1J/hCEA-LTB elicited a greater antibody response than pV1J/hCEA, confirming the adjuvant effect exerted by the LT subunits on the CEA specific immune response (*See* EXAMPLE 11). Thus, the data described herein demonstrate that fusion of the CEA coding sequence to the LTA or LTB cDNA results in an increase the CEA specific immune response. It appears that LTB exerts a greater enhancing effect on the immune response with a prevalent induction of $CD8^+$ T cells, whereas LTA elicits a predominant $CD4^+$ response.

It has also been shown in accordance with the present invention that tolerance to the CEA self antigen can be broken more efficiently, relative to the full-length wild-type CEA cDNA, due to the increased immunogenic properties of the CEA-LTB fusion. The enhancing effect of LTB on the immunogenic properties of CEA was also observed upon injection of a plasmid carrying a fully codon optimized cDNA of the CEA-LTB fusion. Lastly, the results described herein, using adenovirus vectors carrying CEA-LT fusions, indicate that that enhanced immunogenicity of CEA-LT fusions is not limited to plasmid DNA immunization (*see* EXAMPLE 13).

Therefore, the vectors described above may be used in immunogenic compositions and vaccines for preventing the development of adenocarcinomas associated with aberrant CEA expression and/or for treating existing cancers. The vectors of the present invention allow for vaccine development and commercialization by eliminating difficulties with obtaining high expression levels of exogenous CEA in successfully transformed host organisms and by providing a CEA fusion protein which can elicit an enhanced immune response when administered to a mammal such as a human being.

To this end, one aspect of the instant invention is a method of preventing or treating CEA-associated cancer comprising administering to a mammal a vaccine vector comprising a polynucleotide comprising a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal.

In accordance with the method described above, the vaccine vector may be administered for the treatment or prevention of a cancer in any mammal, including but not limited to: lung cancer, breast cancer, and colorectal cancer. In a preferred embodiment of the invention, the mammal is a human.

Further, one of skill in the art may choose any type of vector for use in the treatment and prevention method described. Preferably, the vector is an adenovirus vector or a plasmid vector. In a preferred embodiment of the invention, the vector is an adenoviral vector comprising an adenoviral genome with a deletion in the adenovirus E1 region, and an insert in the adenovirus E1 region, wherein the insert comprises an expression cassette comprising: (a) a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal; and (b) a promoter operably linked to the polynucleotide.

The instant invention further relates to an adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising: (a) a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal; and (b) a promoter operably linked to the polynucleotide.

In a preferred embodiment of this aspect of the invention, the adenovirus vector is an Ad 5 vector.

In another preferred embodiment of the invention, the adenovirus vector is an Ad 6 vector.

In yet another preferred embodiment, the adenovirus vector is an Ad 24 vector.

Also contemplated for use in the present invention is an adenovirus vaccine vector comprising a adenovirus genome that naturally infects a species other than human,

including, but not limited to, chimpanzee adenoviral vectors. A preferred embodiment of this aspect of the invention is a chimp Ad 3 vaccine vector.

In another aspect, the invention relates to a vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising: (a) a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal; and (b) a promoter operably linked to the polynucleotide.

In some embodiments of this invention, the recombinant adenovirus and plasmid-based polynucleotide vaccines disclosed herein are used in various prime/boost combinations in order to induce an enhanced immune response. In this case, the two vectors are administered in a "prime and boost" regimen. For example the first type of vector is administered one or more times, then after a predetermined amount of time, for example, 2 weeks, 1 month, 2 months, six months, or other appropriate interval, a second type of vector is administered one or more times. Preferably the vectors carry expression cassettes encoding the same polynucleotide or combination of polynucleotides. In the embodiment where a plasmid DNA is also used, it is preferred that the vector contain one or more promoters recognized by mammalian or insect cells. In a preferred embodiment, the plasmid would contain a strong promoter such as, but not limited to, the CMV promoter. The synthetic CEA fusion gene or other gene to be expressed would be linked to such a promoter. An example of such a plasmid would be the mammalian expression plasmid V1Jns as described (J. Shiver *et. al.* in *DNA Vaccines*, M. Liu et al. eds., N.Y. Acad. Sci., N.Y., 772:198-208 (1996), which is herein incorporated by reference).

As stated above, an adenoviral vector vaccine and a plasmid vaccine may be administered to a vertebrate as part of a single therapeutic regime to induce an immune response. To this end, the present invention relates to a method of protecting a mammal from a CEA-associated cancer comprising: (a) introducing into the mammal a first vector comprising: i) a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a

substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal; and ii) a promoter operably linked to the polynucleotide.

In one embodiment of the method of protection described above, the first vector is a plasmid and the second vector is an adenovirus vector. In an alternative embodiment, the first vector is an adenovirus vector and the second vector is a plasmid.

In the method described above, the first type of vector may be administered more than once, with each administration of the vector separated by a predetermined amount of time. Such a series of administration of the first type of vector may be followed by administration of a second type of vector one or more times, after a predetermined amount of time has passed. Similar to treatment with the first type of vector, the second type of vector may also be given one time or more than once, following predetermined intervals of time.

The instant invention further relates to a method of treating a mammal suffering from a CEA-associated adenocarcinoma comprising: (a) introducing into the mammal a first vector comprising: i) a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal; and ii) a promoter operably linked to the polynucleotide.

In one embodiment of the method of treatment described above, the first vector is a plasmid and the second vector is an adenovirus vector. In an alternative embodiment, the first vector is an adenovirus vector and the second vector is a plasmid.

In preferred embodiments of the methods described above, the vectors comprise a sequence of nucleotides that encode a CEA-LT fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a LT subunit. In further preferred embodiments, the vector comprises a sequence of nucleotides that encodes a CEA-LTB fusion protein.

The amount of expressible DNA or transcribed RNA to be introduced into a vaccine recipient will depend partially on the strength of the promoters used and on the

immunogenicity of the expressed gene product. In general, an immunologically or prophylactically effective dose of about 1 ng to 100 mg, and preferably about 10 μg to 300 μg of a plasmid vaccine vector is administered directly into muscle tissue. An effective dose for recombinant adenovirus is approximately $10^6 - 10^{12}$ particles and preferably about 10^7—10^{11} particles. Subcutaneous injection, intradermal introduction, impression though the skin, and other modes of administration such as intraperitoneal, intravenous, intramuscular or inhalation delivery are also contemplated.

In preferred embodiments of the present invention, the vaccine vectors are introduced to the recipient through intramuscular injection.

The vaccine vectors of this invention may be naked, i.e., unassociated with any proteins, or other agents which impact on the recipient's immune system. In this case, it is desirable for the vaccine vectors to be in a physiologically acceptable solution, such as, but not limited to, sterile saline or sterile buffered saline. Alternatively, it may be advantageous to administer an agent which assists in the cellular uptake of DNA, such as, but not limited to calcium ion. These agents are generally referred to as transfection facilitating reagents and pharmaceutically acceptable carriers. Those of skill in the art will be able to determine the particular reagent or pharmaceutically acceptable carrier as well as the appropriate time and mode of administration.

All publications mentioned herein are incorporated by reference for the purpose of describing and disclosing methodologies and materials that might be used in connection with the present invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

Having described preferred embodiments of the invention with reference to the accompanying drawings, it is to be understood that the invention is not limited to those precise embodiments, and that various changes and modifications may be effected therein by one skilled in the art without departing from the scope or spirit of the invention as defined in the appended claims.

The following examples illustrate, but do not limit the invention.

EXAMPLE 1

Construction of CEA Fusion Proteins

To assess the effect of LTA and LTB subunits of the *E. coli* heat labile enterotoxin on CEA immunogenicity, a series of vectors were constructed encoding amino acids (hereinafter aa) 1 to 679 of CEA protein fused to either the LTA (aa 18 to 259) or the LTB (aa 21 to 125) coding sequence. A schematic representation of the structure exemplary CEA-LTA and CEA-LTB fusions developed for this study are shown in FIGURE 1. Exemplary nucleotide and amino acid sequences of CEA fusions are shown in FIGURES 2-6.

CEA fusions were engineered by joining the cDNA of the CEA protein deleted of the anchoring sequence to the LT subunits to which the signal peptide coding sequence had been removed. The CEA-fusions coding sequences were cloned into vectors pV1Jns under the control of the human cytomegalovirus (CMV)/intron A promoter plus the bovine growth hormone (BGH) polyadenylation signal. Plasmids pV1J/hCEA-LTA and pV1J/hCEA-LTB carry the wild type cDNA of CEA fused to the coding sequences of LTA and LTB, respectively (see EXAMPLE 2).

All constructs carrying the CEA-LTB fusion were generated by fusing the CEA cDNA from nt 1 to 2037, with the LTB cDNA fragment encompassing nt 64 to 375. The LTB coding sequence was obtained by PCR amplification of *E. coli* genomic DNA using sequence specific primers LTB-S1 5'- T A T T C T A G A T G C T C C C C A G A C T A T T A C A G A A -3' (SEQ ID NO:1) and LTB-A1 5'-T A T G C G G C C G C C T A G T T T T C C A T A C T G A T T G C C G C -3' (SEQ ID NO:2). The amplified DNA was introduced at the 3' end of the CEA coding sequence generating plasmids.

EXAMPLE 2

Plasmid Constructs

pV1J/hCEAopt: Plasmid pCR-hCEAopt was digested with *Eco*RI for 1 hr at 37°C. The resulting 2156 bp insert was purified and cloned into the *Eco*RI site of plasmid pV1JnsB ((Montgomery et al. *DNA Cell Biol* 12(9): 777-83 (1993)).

pV1J/hCEA: Plasmid pCI/hCEA (Song et al. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumour immunity by combined DNA-based

vaccination and nonviral cytokine gene transfer. *Gene Therapy* 7: 481-492 (2000)) was digested with *Eco*RI. The resulting 2109 bp insert was cloned into the *Eco*RI site of plasmid pV1JnsA (Montgomery et al., *supra*).

pV1J/hCEA-LTB and pV1J/hCEA$_{opt}$-LTB: The codon optimized cDNA of LTB was synthetized by oligonucleotide assembly (Geneart GmbH, Regensburg, Germany) and cloned in pCR-script vector (Stratagene, LA Jolla, CA). To generate pV1J/hCEA$_{opt}$-LTB$_{opt}$, LTB$_{opt}$ was amplified by PCR using the following PCR primers: LTBopt-5'XbaI (5' end) 5' – G C T C T A G A G C C C C C C A G A G C A T C A C C G A G C T G T G C - 3'(SEQ ID NO:3) and LTBopt-3'BglII (3' end) 5' – G C T C T A G A A C C C C T C A G A A C A T C A C C G A T C T G T G C G C C - 3' (SEQ ID NO:4). The amplified product was then inserted into the *Xba*I/*Bgl*II sites of plasmid pV1J/hCEA$_{opt}$.

pV1J/hCEA-LTA: The LTA coding sequence corresponding to nt 54 to 774 that encode aa 18 to 259, was amplified by PCR from genomic DNA of *E. coli* using sequence specific primers LTA-S1 5' – T A T T C T A G A T A A T G G C G A C A A A T T A T A C C G - 3' (SEQ ID NO:5) and LTA-A1 5' – T A T G C G G C C G C T C A T A A T T C A T C C C G A A T T C T G T T - 3' (SEQ ID NO:6). The amplified DNA was digested with appropriate restriction enzymes and inserted into plasmid pV1J/hCEA.

pV1J/rhCEAopt-LTB: A 3' fragment of the rhesus monkey CEA cDNA (nt 1641 to 2026), which was codon-optimized for high level expression in human cells, was amplified by PCR from pV1J-rhCEAopt. The amplified cDNA lacked the GPI anchor coding sequence and carried the *Xba*I/*Bgl*II restriction sites. This fragment was inserted into the *Pst*I site of pCR-blunt-rhCEAopt, thus obtaining the intermediate pCR-blunt-rhCEAopt XbaI/BglIII. rhCEAopt was extracted as a *Bgl*II/*Sal*I fragment and cloned in the same sites in pV1J-nsB, thus obtaining pV1J-rhCEAopt XbaI/BglII. LTBopt was amplified by PCR from pCR-script-LTBopt adding *Xba*I and *Bgl*II sites at 5' and 3' ends, respectively, and was cloned in pV1J-rhCEAopt XbaI/BglII, thus obtaining pV1J-rhCEAopt-LTBopt.

EXAMPLE 3

Adenovirus Vectors

Ad5/hCEA$_{opt}$: Plasmid pCR-hCEAopt was digested with *Eco*RI. The resulting 2156 bp insert was purified and cloned into the *Eco*RI of the polyMRK-Ad5 shuttle plasmid.

Ad5/CEA: The shuttle plasmid pMRK-hCEA for generation of Ad5 vector was obtained by digesting plasmid pDelta1sp1B/hCEA with *Ssp*I and *Eco*RV. The 9.52kb fragment was then ligated with a 1272 bp *Bgl*II/*Bam*HI-restricted, Klenow-treated product from plasmid polyMRK. A *Pac*I/*Stu*I fragment from pMRK-hCEA and pMRK-hCEAopt containing the expression cassette for hCEA and E1 flanking Ad5 regions was recombined to *Cla*I linearized plasmid pAd5 in BJ5183 *E. coli* cells. The resulting plasmids were pAd5-hCEA and pAd5-hCEAopt, respectively. Both plasmids were cut with *Pac*I to release the Ad ITRs and transfected in PerC-6 cells. Ad5 vectors amplification was carried out by serial passage. MRKAd5/hCEA and MRKAd5/hCEAopt were purified through standard CsCl gradient purification and extensively dialyzed against A105 buffer (5mM Tris-Cl pH 8.0, 1mM $MgCl_2$, 75 mM NaCl, 5% Sucrose, 0.005 Tween 20).

Ad5/hCEAopt-LTB: Plasmid pMRK-hCEAopt-LTB was constructed by cutting polyMRK-Ad5 shuttle plasmid with *Swa*I and by ligating the linearized vector with the 2300 bp DNA fragment derived from pV1J/hCEAopt-LTB that had been restricted with *Eco*RI, *Bgl*II and treated with Klenow. The pMRK-hCEAopt-LTB was linearized and recombined into the Ad genome as indicated above.

EXAMPLE 4

Comparative Expression Efficiency of Various CEA Fusion Constructs

The use of codon optimized cDNAs for genetic vaccination against viral diseases has been shown to elicit a greater immune response due, at least in part, to an increased expression of the target protein. To verify whether the LTB coding sequence would also enhance the immunogenic properties of the CEA cDNA designed to incorporate human-preferred (humanized) codons for each amino acid residue, plasmid pV1J/hCEAopt-LTB was also constructed. Finally, a fully codon optimized version of the CEA-LTB fusion was also constructed using a synthetic codon optimized cDNA of LTB to generate plasmid pV1J/hCEA-LTBopt.

To determine whether the LTB effect on CEA immunogenicity was not limited to plasmid DNA immunization, an Adenovirus type 5 vector encoding the CEAopt-LTB fusion flanked by the CMV/intron A promoter and the BGH polyadenylation signal was also constructed. The molecular mass of the CEA fusion proteins expressed by both plasmid and

Ad vectors did not differ from that derived from the corresponding vectors encoding the full length form of CEA cDNA (data not shown).

To compare the efficiency of expression of the vectors encoding the CEA-LTA and CEA-LTB fusions and that of the cDNA of full length CEA, HeLa cells were transfected with plasmids pV1J/hCEA-LTA, and pV1J/hCEA-LTB. The CEA expression of these constructs was compared to that of the corresponding plasmid carrying the wt cDNA of CEA, pV1J/hCEA. Similarly, plasmid pV1J/hCEAopt-LTB expression efficiency was compared to that of pV1J/hCEAopt. Expression efficiency of these constructs were determined two days post transfection by monitoring the amount of CEA protein in cell extracts.

Transfection of plasmids pV1J/hCEA-LTA and pV1J/hCEA-LTB yielded approximately two fold higher amounts of CEA protein (183 and 139 μg/l, respectively, FIGURE 8A) detected in the culture supernatant as compared to plasmid pV1J/CEA (91 μg/l). Similarly, the expression efficiency of constructs pV1J/hCEAopt and pV1J/hCEAopt-LTB was also comparable (113 and 136 μg/l, respectively; FIGURE 8B). Finally, the expression efficiency of the Ad/hCEAopt and Ad/hCEAopt-LTB was also compared by infecting HeLa cells at different moi. The CEA expression efficiency of these two vectors was comparable at moi 1000 (1790 and 1400 μg/l, respectively, FIGURE 9) whereas at moi 100, vector Ad/hCEAopt-LTB yielded approximately four fold lower amounts of CEA protein detectable in the culture supernatant than Ad/hCEAopt (390 and 1500 μg/l, respectively).

Thus, these results indicate that the cDNA encoding the CEA-LTA and CEA-LTB fusion proteins are expressed with equivalent efficiency to that of the corresponding cDNA encoding the full length CEA protein. Additionally, the comparable CEA expression of these cDNAs is not influenced by the type of the gene transfer vehicle utilized for their delivery.

EXAMPLE 5

Detection of CEA Expression.

Expression of hCEA by plasmid and Ad vectors was monitored by Western blot analysis and ELISA. Plasmids were transfected in HeLa cells with Lipofectamine 2000 (Life Technologies). Adenovirus infections of HeLa cells were performed in serum free

medium for 30 min at 37°C, and then fresh medium was added. After 48hr incubation, whole cell lysates were harvested. The CEA protein present in the cell lysates was detected by Western blot analysis using a rabbit polyclonal antiserum. The protein was detected as a 180-200 kDa band. The amount of expressed CEA was detected in the cell lysates using the Direct Elisa CEA Kit (DBC-Diagnostics Biochem Canada Inc).

EXAMPLE 6

Peptides

Lyophilized hCEA peptides were purchased from Bio-Synthesis and resuspended in DMSO at 40 mg/ml. Pools of peptides 15 aa long overlapping by 11 residues were assembled as described in the Results section. Final concentrations were the following: pool A=1.2 mg/ml, pool B 0.89 mg/ml, pool C 0.89 mg/ml, pool D 0.8 mg/ml. Peptides were stored at –80°C.

EXAMPLE 7

Mice Immunization

Female C57BL/6 mice (H-2^b) were purchased from Charles River (Lecco, Italy). HLA-A2.1 mice (HHD) were kindly provided by F. Lemmonier (Institute Pasteur, Paris, France). C57BL/DR4 mice were purchased from Taconic (Germantown, NY). CEA.tg mice (H-2^b) were provided by J. Primus (Vanderbilt University) and kept in standard conditions. Fifty micrograms of plasmid DNA were electroinjected in a 50µl volume in mice quadriceps as previously described (Rizzuto et al. *Proc. Natl. Acad. Sci. U.S.A.* 96(11): 6417-22 (1999)). Ad injections were carried out in mice quadriceps in 50µl volume. Humoral and cell mediated immune response were analyzed at the indicated time.

EXAMPLE 8

Antibody Detection and Titration.

Sera for antibody titration were obtained by retro-orbital bleeding. ELISA plates (Nunc maxisorp) were coated with 100ng/well with CEA protein (Fitzgerald, highly pure CEA), diluted in coating buffer (50mM $NaHCO_3$, pH 9.4) and incubated O/N at 4°C. Plates were then blocked with PBS containing 5% BSA for 1 hr at 37°C. Mouse sera were diluted in PBS 5% BSA (dilution 1/50 to evaluate seroconversion rate; dilutions from 1:10 to 1:31,2150 to evaluate titer). Pre-immune sera were used as background. Diluted sera were incubated O/N at 4°C. Washes were carried out with PBS 1% BSA, 0.05% Tween 20. Secondary antibody (goat anti-mouse, IgG Peroxidase, Sigma) was diluted 1/2000 in PBS, 5% BSA and incubated 2-3 hr at RT on a shaker. After washing, plates were developed with 100µl/well of TMB substrate (Pierce Biotechnology, Inc., Rockford, IL). Reaction was stopped with 25 µl/well of 1M H_2SO_4 solution and plates were read at 450nm/620 nm. Anti-CEA serum titers were calculated as the reciprocal limiting dilution of serum producing an absorbance at least 3-fold greater than the absorbance of autologous pre-immune serum at the same dilution.

EXAMPLE 9

IFN-γ ELISPOT Assay

Ninety-six wells MAIP plates (Millipore Corp., Billerica, MA) were coated with 100 µl/ well of purified rat anti-mouse IFN-γ (IgG1, clone R4-6A2, Pharmingen) diluted to 2.5 µg/ml in sterile PBS. After washing with PBS, blocking of plates was carried out with 200 µl/well of R10 medium for 2 hrs at 37°C.

Splenocytes were obtained by removing the spleen from the euthanized mice in a sterile manner and by spleen disruption by grating on a metal grid. Red blood cells were removed by osmotic lysis by adding 1 ml of 0.1X PBS to the cell pellet and vortexing for approximately 15s. One ml of 2x PBS was then added and the volume was brought to 4ml with 1x PBS. Cells were pelleted by centrifugation at 1200 rpm for 10 min at RT, and the pellet was resuspended in 1 ml R10 medium. Viable cells were counted using Türks staining.

Splenocytes were plated at $5x10^5$ and $2.5x10^5$ cells/well in duplicate and incubated for 20h at 37°C with 1μg/ml suspension of each peptide. Concanavalin A (ConA) was used as positive internal control for each mouse at 5μg/ml. After washing with PBS, 0.05% Tween 20, plates were incubated O/N at 4°C with 50μl/well of biotin-conjugated rat anti-mouse IFNγ (RatIgG1, clone XMG 1.2, PharMingen) diluted to 1:2500 in assay buffer. After extensive washing, plates were developed by adding 50 μl/well NBT/B-CIP (Pierce) until development of spots was clearly visible. The reaction was stopped by washing plates thoroughly with distilled water. Plates were air dried and spots were then counted using an automated ELISPOT reader.

EXAMPLE 10

Intracellular Cytokine Staining.

One to two millions mouse splenocytes or PBMC in 1ml RPMI 10% FCS were incubated with pool of peptides (5-6 μg/ml final concentration of each peptide) and brefeldin A (1 μg/ml; BD Pharmingen cat #555028/2300kk) at 37°C and 5% CO_2 for 12-16 hours. Cells were then washed with FACS buffer (PBS 1% FBS, 0.01% NaN3) and incubated with purified anti-mouse CD16/CD32 Fc block (BD Pharmingen cat # 553142) for 15 min at 4°C. Cells were then washed and stained with surface antibodies: CD4-PE conjugated anti-mouse (BD Pharmingen, cat.# 553049), PercP CD8 conjugated anti mouse (BD Pharmingen cat# 553036) and APC- conjugated anti-mouse CD3e (BD Pharmingen cat# 553066) for 30 minutes at room temperature in the dark. After the washing cells were fixed and permeabilized with Cytofix-Cytoperm Solution (BD Pharmingen cat #555028/2300kk) for 20 min at 4°C in the dark. After washing with PermWash Solution (BD Pharmingen cat #555028/2300kk) cells were incubated with the IFNγ-FITC antibodies (BD Pharmingen). Cells were then washed, fixed with formaldehyde 1% in PBS and analyzed on a FACS-Calibur flow cytometer, using CellQuest software (Becton Dickinson, San Jose, CA).

EXAMPLE 11

Immunogenicity of CEA-LT Fusions

To examine the immune responses induced by the plasmids encoding the CEA-LTA and CEA-LTB fusions, groups of 9 C57BL/6 mice were immunized with two injections i.m. of 50 μg each of plasmids pV1J/hCEA, pV1J/hCEA-LTA and pV1J/hCEA-LTB. Additionally, to verify whether coexpression of the CEA-LTA and CEA-LTB fusion proteins could have an additive effect on the immunogenicity of the CEA protein, a group of mice was immunized by coinjecting 25 μg each of plasmids pV1J/hCEA-LTA and pV1J/hCEA-LTB. Immunizations were administered three weeks apart. The plasmid DNA was routinely electroinjected into mouse skeletal muscle in view of the enhanced transduction and immunogenicity connected with this particular procedure (Zucchelli et al. *J. Virol.* 74: 11598-11607 (2000); Widera et al. *J. Immunol.* 164: 4635-4640 (2000)).

The cellular immunity elicited by the different plasmids was measured by ELISPOT assay 2 weeks after the last injection. Antigen-specific IFNγ secretion from stimulated splenocytes was measured using four pools of 15mer peptides overlapping by 11 aa and encompassing the entire CEA glycoprotein. Pool A covers aa 1 to 147, pool B aa 137 to 237, pool C aa 317 to 507, and pool D aa 497 to 703. As a negative control, cytokine production was also measured upon stimulation of the splenocytes with DMSO at the same concentration utilized to solubilize the CEA peptides.

The immune response elicited by DNA vaccination in C57BL/6 mice was primarily biased towards the C-terminal region of the protein since the SFC values detected with the peptide pool A were slightly above background with all constructs (FIGURE 10). The pV1J/hCEA-LTB vaccination regimen was superior to that elicited by pV1J/hCEA as indicated by the higher geometric mean values of the SFC detected with peptide pools B, C and D (pV1J/hCEA-LTB: 482, 1436, and 2054 SFC/10^6 splenocytes, respectively; pV1J/hCEA: 45, 350, and 264 SFC/10^6 splenocytes, respectively). Similarly, plasmid pV1J/hCEA-LTA had also an enhancing effect on the CEA specific immune response when compared to pV1J/hCEA. However, the increase in immune response was only observed with peptide pools C and D (925 and 528 SFC/10^6 splenocytes, respectively), while the immune response measured with peptide pool B was low (15 SFC/10^6 splenocytes). Additionally, coinjection of plasmids pV1J/hCEA-LTA and pV1J/hCEA-LTB did not have a significant synergic effect on the immune response to CEA when compared to the immune

response measured in the pV1J/hCEA-LTB treated group, but rather, it resulted in a decrease of the SFC values detected with peptides pool B and D (210 and 528 SFC/10^6 splenocytes, respectively).

To define the T-cell specificity elicited upon vaccination with the different CEA constructs, IFNγ intracellular staining was carried out on pooled splenocytes from injected mice using peptide pool D. A $CD8^+$-specific response was detected in mice injected with pV1J/hCEA-LTB (4.5%) superior to that detected with pV1J/hCEA-LTA and pV1J/hCEA (0.14% and 0.8%, respectively, FIGURE 10B). In contrast, pV1J/CEA-LTA elicited a strong $CD4^+$-specific response (1.21%) greater than that observed with pV1J/hCEA-LTB and pV1J/hCEA (0.55% and 0.58%, respectively).

The induction of the humoral immune response to CEA was examined by measuring antigen specific antibodies (FIGURE 11). Both plasmids pV1J/hCEA-LTA and pV1J/hCEA-LTB elicited a greater antibody response than pV1J/hCEA, confirming the adjuvant effect exerted by the LT subunits on the CEA specific immune response. Thus, these data demonstrate that fusion of the CEA coding sequence to the LTA or LTB cDNA results in an increase the CEA specific immune response. However, LTB appears to have a greater enhancing effect on the immune response with a prevalent induction of $CD8^+$ T cells, whereas LTA elicits a predominant $CD4^+$ response.

EXAMPLE 12

Immunogenicity of CEA-LTB Fusions in Different Mouse Strains.

To determine whether the enhancing effect of the LT subunits on the CEA specific immune response was not limited to a single mouse genetic background, DNA based immunizations were carried out in BALB/c, C57/DR4 and HLA-A2.1 (HHD) mice. The BALB/c mice were chosen in view of their immunocompetence, being a mouse strain extremely reactive to immunization regimens of various sorts. The HHD transgenic mice express the human MHC class I genes. Similarly, C57/DR4 transgenic mice carry the human MHC class II genes. Thus, these two transgenic mouse strains may provide information as to the immunoreactivity of the CEA-LT fusions in the context of human MHC class I and II haplotypes.

The CEA specific immune response in BALB/c mice was first assessed by ELISPOT assay. Enhancement of the antigen specific immune response upon immunization

with plasmid pV1J/hCEA-LTB was detected with peptide pools A, B, C, D (pV1J/hCEA-LTB: 166, 1353, 796, 899 SFC/10^6 splenocytes, respectively; pV1J/hCEA: 57, 312, 327, 318, SFC/10^6 splenocytes respectively, FIGURE 12). As observed in the C57BL/6 mice, the N-terminal region of the CEA protein appeared to be the least immunogenic as compared to other sections of the tumor antigen. pV1J/hCEA-LTA immunization also yielded an increase in the antigen specific immune response as compared to pV1J/hCEA. The increase in the immune response was detected with peptide pools B, C and D (936, 727, and 650 SFC/10^6 splenocytes, respectively). Additionally, coinjection of the two plasmids pV1J/hCEA-LTA and pV1J/hCEA-LTB yielded a significant additive effect thats was detected mainly with peptide pools C and D (1783 and 2141 SFC/10^6 splenocytes, respectively).

The CEA specific immune response in C57/DR4 mice was considerably enhanced by the immunization with pV1J/hCEA-LTB, and was detected only peptide pool D (FIGURE 13). IFNγ intracellular staining performed on pooled PBMC from injected mice showed that the $CD8^+$ response to CEA was highest in mice immunized with pV1J/hCEA-LTB (15.32%), whereas was very weak in the pV1J/hCEA treated group (0.5%). pV1J/CEA-LTA immunization increased the antigen specific immune response only moderately (0.43%), and did not further enhance the CEA immunogenicity when coinjected with the construct encoding the CEA-LTB fusion (13.44 %). Interestingly, no significant $CD4^+$ T cell response was detected in the immunized mice (data not shown).

The immune response elicited by the different CEA encoding plasmids was assessed in HHD mice by performing IFNγ intracellular staining on pooled PBMC. The immune response was only detected with peptide pools B and D, and as shown in FIGURE 14, immunization with pV1J/hCEA-LTB resulted in more than 10 fold increase in the $CD8^+$ response to the target antigens. In contrast, no increase in the immune response was detected using pV1J/hCEA-LTA either alone or upon coinjection with pV1J/hCEA-LTB. No $CD4^+$ T cell response was detected in the immunized mice (data not shown).

Taken together, these data confirm that fusion of the LTB coding sequence to CEA results in a considerable increase in the antigen specific immune response. Interestingly, this response is predominantly $CD8^+$-specific and can be observed in different mouse strains, thus indicating that the enhancing effect exerted by the LT subunit is not genotype restricted.

EXAMPLE 13

Tolerance to Human CEA in Transgenic Mice.

To determine whether the enhanced immunogenic properties of the hCEA-LTB fusion would break tolerance more efficiently to human CEA, hCEA transgenic mice were immunized with vectors carrying either the fully codon optimized cDNA of hCEA or CEA-LTB. These transgenic mice carry the entire human CEA gene and flanking sequences and express the hCEA protein in the intestine, mainly in the cecum and colon. Thus, this mouse line is a useful model for studying the safety and efficacy of immunotherapy strategies directed against this tumour self antigen (Clarke et al., *Cancer Research* 58: 1469-1477 (1998)).

Immunization with pV1J/hCEA-LTBopt resulted in a significant increase in the CEA specific immune response measured by IFNγ intracellular staining on PBMC of the injected mice (FIGURE 15A). The enhancement of the T cell response was detected with peptide pool D and was predominantly $CD8^+$. Additionally, also the CEA specific humoral response was increased in the CEA-LTB treated mice as shown by the 47 fold increase in the geometric mean values of the Ab titer as compared to the pV1J/hCEAopt treated group (FIGURE 15B).

To determine whether the enhancing effect exerted by LTB on the CEA specific immune response could also be observed upon immunization with vectors other than plasmid DNA, groups of 12 CEA tg mice were immunized with Ad5/hCEAopt-LTB and Ad/hCEAopt at a dose of $1x10^7$, $1x10^8$, and $1x10^9$ vp. Mice were subjected to two injections two weeks apart and the immune response was measured by IFNγ intracellular staining on PBMC two weeks after the last injection. The immune response was assessed using the peptide pool D. Ad/hCEAopt-LTB was more immunogenic than Ad/hCEAopt since significant immune responses to CEA could be detected with the $1x10^8$vp dose, whereas $1x10^9$ vp of Ad/hCEAopt were necessary to break tolerance to the target antigen (FIGURE 16). No $CD4^+$ response could be detected in any of the immunized mice (data not shown).

These data confirm that tolerance to this self antigen can be broken more efficiently due to the increased immunogenic properties of the CEA-LTB fusion. Furthermore, the enhancing effect of LTB on the immunogenic properties of CEA is also observable upon injection of plasmid carrying the fully codon optimized cDNA of the CEA-

LTB fusion. Lastly, these results indicate that that enhanced immunogenicity of CEA-LTB is not limited to plasmid DNA immunization.

EXAMPLE 14

Tumor Growth Kinetics in CEA Transgenic Mice Immunized with CEA-LTB Fusions

It was deemed appropriate to ascertain whether the increased immunogenicity of the CEA-LTB fusion would also lead to an enhanced therapeutic effect capable of interfering with tumor progression. For this purpose, groups of 10 CEA-tg mice were subjected to 5 weekly injections of plasmids pV1J/hCEAopt or pV1J/CEAopt-LTB followed by a final boost with $1x10^{10}$ vp of the corresponding Ad vector. In view of recent reports that indicate that high levels of cellular immunity can be induced against viral and bacterial antigens by utilizing plasmid DNA prime-Ad boost modality, the same immunization protocol was employed in this study. Two weeks after the last immunization, the CEA tg mice were challenged with a subcutaneous injection of $5x10^5$ MC38-CEA tumor cells. This syngenic cell line was derived from a chemically induced colon cancer and expresses CEA. Tumor development in mock treated mice was detected by 22 days post challenge as all the treated mice were no longer tumor free (FIGURE 17A). Additionally, there was a concomitant increase in the average size of the tumor mass that reached significant volume by 34 days post challenge. Mice vaccinated with vectors encoding pV1J/hCEAopt showed a partial resistance to tumor development since 2 out of 10 treated mice remained tumor free at day 34 post challenge. The average size of the tumors of this group was smaller than that observed in the mock treated mice. Immunization with vectors encoding the CEAopt-LTB fusion resulted in a significant protective effect from tumor development. Five out of 10 treated mice remained tumor free at day 34 post challenge, and the average size of the tumor mass in this group was significantly smaller that that observed in the mock or pV1J/hCEAopt treated mice. Thus, these results indicate that the enhanced CEA-specific immune response associated with vectors encoding the CEA-LTB fusion correlates with a significant antitumor effect resulting in partial protection from tumor growth and reduced growth kinetics of the tumor mass.

WHAT IS CLAIMED IS:

1. A nucleic acid molecule comprising a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal.

2. The nucleic acid molecule of claim 1, wherein the CEA protein is a human CEA protein or variant thereof.

3. The nucleic acid molecule of claim 1, wherein the CEA protein is a rhesus monkey CEA protein or variant thereof.

4. The nucleic acid molecule of claim 1, wherein the CEA protein is N-terminally truncated.

5. The nucleic acid molecule of claim 1, wherein the CEA protein is C-terminally truncated.

6. The nucleic acid molecule of claim 5, wherein the C-terminal truncation comprises amino acids 679 – 702 of SEQ ID NO:20.

7. The nucleic acid molecule of claim 1, wherein the bacterial toxin comprises a substantial portion of a subunit of heat labile enterotoxin of *E. coli* (LT).

8. The nucleic acid molecule of claim 7, wherein the bacterial toxin is LT subunit A or a substantial portion thereof.

9. The nucleic acid molecule of claim 7, wherein the bacterial toxin is LT subunit B or a substantial portion thereof.

10. The nucleic acid molecule of claim 9, wherein the LT subunit B is truncated of its signal sequence.

11. The nucleic acid molecule of claim 1, wherein the sequence of nucleotides is selected from the group consisting of SEQ ID NOs:7, 9, 11, 12, and 14.

12. A nucleic acid molecule that hybridizes under high stringency conditions to the nucleic acid molecule of claim 11.

13. The nucleic acid molecule of claim 7, wherein the C-terminal end of the CEA protein is fused to the N-terminal end of the LT subunit.

14. A vector comprising the nucleic acid molecule of claim 1.

15. The vector of claim 14, wherein the vector is an adenovirus vector or a plasmid vector.

16 The vector of claim 15, wherein the vector is an Ad 5 vector.

17. The vector of claim 15, wherein the vector is an Ad 6 vector.

18. The vector of claim 15, wherein the vector is an Ad 24 vector.

19. The vector of claim 15, wherein the vector is a chimp Ad vector.

20. The vector of claim 19, wherein the vector is a chimp Ad 3 vector.

21. The vector of claim 14, wherein the vector is pV1JnsB.

22. A host cell comprising the vector of claim 14.

23. A process for expressing a CEA fusion protein in a recombinant host cell, comprising:

(a) introducing a vector comprising the nucleic acid molecule of claim 1 into a suitable host cell; and,

(b) culturing the host cell under conditions which allow expression of said human CEA fusion protein.

24. A purified CEA fusion protein encoded by the nucleic acid molecule of claim 1.

25. The purified CEA fusion protein of claim 24, wherein the fusion protein comprises a sequence of amino acids selected from the group consisting of : SEQ ID NOS:8, 10, 13, and 15.

26. A method of preventing or treating cancer comprising administering to a mammal a vaccine vector comprising a polynucleotide comprising a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal.

27. A method according to claim 26 wherein the mammal is human.

28. A method according to claim 27 wherein the vector is an adenovirus vector or a plasmid vector.

29. A method according to claim 28 wherein the vector is an adenoviral vector comprising an adenoviral genome with a deletion in the adenovirus E1 region, and an insert in the adenovirus E1 region, wherein the insert comprises an expression cassette comprising:

(a) a polynucleotide comprising sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal; and,

(b) a promoter operably linked to the polynucleotide.

30. A method according to claim 28 wherein the vector is a plasmid vaccine vector, which comprises a plasmid portion and an expressible cassette comprising

(a) a polynucleotide comprising a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant

thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mamma; and,

(b) a promoter operably linked to the polynucleotide.

31. An adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising:

(a) a polynucleotide comprising a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal; and

(b) a promoter operably linked to the polynucleotide.

32. An adenovirus vector according to claim 31 which is an Ad 5 vector.

33. An adenovirus vector according to claim 31 which is an Ad 6 vector.

34. An adenovirus vector according to claim 31 which is an Ad 24 vector.

35. A vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising:

(a) a polynucleotide comprising a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal; and,

(b) a promoter operably linked to the polynucleotide.

36. A method of treating a mammal suffering from or predisposed to a CEA-associated cancer comprising:

(a) introducing into the mammal a first vector comprising:

(i) a polynucleotide comprising a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal; and,

(ii) a promoter operably linked to the polynucleotide;

(b) allowing a predetermined amount of time to pass; and

(c) introducing into the mammal a second vector comprising:

(i) a polynucleotide comprising a sequence of nucleotides that encodes a CEA fusion protein, wherein the CEA fusion protein comprises a CEA protein or variant thereof, fused to a substantial portion of a bacterial toxin or subunit thereof and wherein the fusion protein is capable of producing an immune response in a mammal; and

(ii) a promoter operably linked to the polynucleotide.

37. A method according to claim 36 wherein the first vector is a plasmid and the second vector is an adenovirus vector.

38. A method according to claim 36 wherein the first vector is an adenovirus vector and the second vector is a plasmid.

ABSTRACT OF THE DISCLOSURE

Polynucleotides encoding carcinoembryonic antigen (CEA) fusion proteins are provided, the CEA fusion proteins comprising a CEA protein, or functional variant thereof, fused to a substantial portion of a bacterial toxin. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type CEA. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding CEA fusion proteins and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

FIGURE 1





TR0073 PV

FIGURE 2A

hCEA-LTA Nucleotide Sequence

```
   1  ATGGAGTCTC CCTCGGCCCC TCCCCACAGA TGGTGCATCC CCTGGCAGAG
  51  GCTCCTGCTC ACAGCCTCAC TTCTAACCTT CTGGAACCCG CCCACCACTG
 101  CCAAGCTCAC TATTGAATCC ACGCCGTTCA ATGTCGCAGA GGGGAAGGAG
 151  GTGCTTCTAC TTGTCCACAA TCTGCCCCAG CATCTTTTTG GCTACAGCTG
 201  GTACAAAGGT GAAAGAGTGG ATGGCAACCG TCAAATTATA GGATATGTAA
 251  TAGGAACTCA ACAAGCTACC CCAGGGCCCG CATACAGTGG TCGAGAGATA
 301  ATATACCCCA ATGCATCCCT GCTGATCCAG AACATCATCC AGAATGACAC
 351  AGGATTCTAC ACCCTACACG TCATAAAGTC AGATCTTGTG AATGAAGAAG
 401  CAACTGGCCA GTTCCGGGTA TACCCGGAGC TGCCCAAGCC CTCCATCTCC
 451  AGCAACAACT CCAAACCCGT GGAGGACAAG GATGCTGTGG CCTTCACCTG
 501  TGAACCTGAG ACTCAGGACG CAACCTACCT GTGGTGGGTA AACAATCAGA
 551  GCCTCCCGGT CAGTCCCAGG CTGCAGCTGT CCAATGGCAA CAGGACCCTC
 601  ACTCTATTCA ATGTCACAAG AAATGACACA GCAAGCTACA AATGTGAAAC
 651  CCAGAACCCA GTGAGTGCCA GGCGCAGTGA TTCAGTCATC CTGAATGTCC
 701  TCTATGGCCC GGATGCCCCC ACCATTTCCC CTCTAAACAC ATCTTACAGA
 751  TCAGGGGAAA ATCTGAACCT CTCCTGCCAC GCAGCCTCTA ACCCACCTGC
 801  ACAGTACTCT TGGTTTGTCA ATGGGACTTT CCAGCAATCC ACCCAAGAGC
 851  TCTTTATCCC CAACATCACT GTGAATAATA GTGGATCCTA TACGTGCCAA
 901  GCCCATAACT CAGACACTGG CCTCAATAGG ACCACAGTCA CGACGATCAC
 951  AGTCTATGCA GAGCCACCCA AACCCTTCAT CACCAGCAAC AACTCCAACC
1001  CCGTGGAGGA TGAGGATGCT GTAGCCTTAA CCTGTGAACC TGAGATTCAG
1051  AACACAACCT ACCTGTGGTG GGTAAATAAT CAGAGCCTCC CGGTCAGTCC
1101  CAGGCTGCAG CTGTCCAATG ACAACAGGAC CCTCACTCTA CTCAGTGTCA
1151  CAAGGAATGA TGTAGGACCC TATGAGTGTG GAATCCAGAA CGAATTAAGT
1201  GTTGACCACA GCGACCCAGT CATCCTGAAT GTCCTCTATG GCCCAGACGA
1251  CCCCACCATT TCCCCCTCAT ACACCTATTA CCGTCCAGGG GTGAACCTCA
1301  GCCTCTCCTG CCATGCAGCC TCTAACCCAC CTGCACAGTA TTCTTGGCTG
1351  ATTGATGGGA ACATCCAGCA ACACACACAA GAGCTCTTTA TCTCCAACAT
1401  CACTGAGAAG AACAGCGGAC TCTATACCTG CCAGGCCAAT AACTCAGCCA
1451  GTGGCCACAG CAGGACTACA GTCAAGACAA TCACAGTCTC TGCGGAGCTG
1501  CCCAAGCCCT CCATCTCCAG CAACAACTCC AAACCCGTGG AGGACAAGGA
1515  TGCTGTGGCC TTCACCTGTG AACCTGAGGC TCAGAACACA ACCTACCTGT
1601  GGTGGGTAAA TGGTCAGAGC CTCCCAGTCA GTCCCAGGCT GCAGCTGTCC
1651  AATGGCAACA GGACCCTCAC TCTATTCAAT GTCACAAGAA ATGACGCAAG
1701  AGCCTATGTA TGTGGAATCC AGAACTCAGT GAGTGCAAAC CGCAGTGACC
1751  CAGTCACCCT GGATGTCCTC TATGGGCCGG ACACCCCCAT CATTTCCCCC
1801  CCAGACTCGT CTTACCTTTC GGGAGCGAAC CTCAACCTCT CCTGCCACTC
1851  GGCCTCTAAC CCATCCCCGC AGTATTCTTG GCGTATCAAT GGGATACCGC
1901  AGCAACACAC ACAAGTTCTC TTTATCGCCA AAATCACGCC AAATAATAAC
1951  GGGACCTATG CCTGTTTTGT CTCTAACTTG GCTACTGGCC GCAATAATTC
2001  CATAGTCAAG AGCATCACAG TCTCTGCATC TGGAACTCTA GTTAATGGCG
2051  ACAAATTATA CCGTGCTGAC TCTAGACCCC CAGATGAAAT AAAACGTTCC
2101  GGAGGTCTTA TGCCCAGAGG GCATAATGAG TACTTCGATA GAGGAACTCA
2151  AATGAATATT AATCTTTATG ATCACGCGAG AGGAACACAA ACCGGCTTTG
2201  TCAGATATGA TGACGGATAT GTTTCCACTT CTCTTAGTTT GAGAAGTGCT
2251  CACTTAGCAG GACAGTCTAT ATTATCAGGA TATTCCACTT ACTATATATA
2301  TGTTATAGCG ACAGCACCAA ATATGTTTAA TGTTAATGAT GTATTAGGCG
2351  TATACAGCCC TCACCCATAT GAACAGGAGG TTTCTGCGTT AGGTGGAATA
2401  CCATATTCTC AGATATATGG ATGGTATCGT GTTAATTTTG GTGTAATTGA
2451  TGAACGATTA CATCGTAACA GGGAATATAG AGACCGGTAT TACAGAAATC
2501  TGAATATAGC TCCGGCAGAG GATGGTTACA GATTAGCAGG TTTCCCACCG
2551  GATCACCAAG CTTGGAGAGA AGAACCCTGG ATTCATCATG CACCACAAGG
```

TR0073PV

2601 TTGTGGAAAT TCATCAAGAA CAATTACAGA TGATACTTGT AATGAGGAGA
2651 CCCAGAATCT GAGCACAATA TATCTCAGGA AATATCAATC AAAAGTTAAG
2701 AGGCAGATAT TTTCAGACTA TCAGTCAGAG GTTGACATAT ATAACAGAAT
TCGGGATGAA TTATGA (SEQ ID NO:7)

TR0073PV

FIGURE 2B

CEA-LTA Amino acid sequence

```
  1   MESPSAPPHR WCIPWQRLLL TASLLTFWNP PTTAKLTIES TPFNVAEGKE
 51   VLLLVHNLPQ HLFGYSWYKG ERVDGNRQII GYVIGTQQAT PGPAYSGREI
101   IYPNASLLIQ NIIQNDTGFY TLHVIKSDLV NEEATGQFRV YPELPKPSIS
151   SNNSKPVEDK DAVAFTCEPE TQDATYLWWV NNQSLPVSPR LQLSNGNRTL
201   TLFNVTRNDT ASYKCETQNP VSARRSDSVI LNVLYGPDAP TISPLNTSYR
251   SGENLNLSCH AASNPPAQYS WFVNGTFQQS TQELFIPNIT VNNSGSYTCQ
301   AHNSDTGLNR TTVTTITVYA EPPKPFITSN NSNPVEDEDA VALTCEPEIQ
351   NTTYLWWVNN QSLPVSPRLQ LSNDNRTLTL LSVTRNDVGP YECGIQNELS
401   VDHSDPVILN VLYGPDDPTI SPSYTYYRPG VNLSLSCHAA SNPPAQYSWL
451   IDGNIQQHTQ ELFISNITEK NSGLYTCQAN NSASGHSRTT VKTITVSAEL
501   PKPSISSNNS KPVEDKDAVA FTCEPEAQNT TYLWWVNGQS LPVSPRLQLS
551   NGNRTLTLFN VTRNDARAYV CGIQNSVSAN RSDPVTLDVL YGPDTPIISP
601   PDSSYLSGAN LNLSCHSASN PSPQYSWRIN GIPQQHTQVL FIAKITPNNN
651   GTYACFVSNL ATGRNNSIVK SITVSASGTL VNGDKLYRAD SRPPDEIKRS
701   GGLMPRGHNE YFDRGTQMNI NLYDHARGTQ TGFVRYDDGY VSTSLSLRSA
751   HLAGQSILSG YSTYYIYVIA TAPNMFNVND VLGVYSPHPY EQEVSALGGI
801   PYSQIYGWYR VNFGVIDERL HRNREYRDRY YRNLNIAPAE DGYRLAGFPP
851   DHQAWREEPW IHHAPQGCGN SSRTITDDTC NEETQNLSTI YLRKYQSKVK
901   RQIFSDYQSE VDIYNRIRDE L (SEQ ID NO:8)
```

R0073PV

FIGURE 3A

hCEA-LTB Coding Sequence

```
   1  ATGGAGTCTC CCTCGGCCCC TCCCCACAGA TGGTGCATCC CCTGGCAGAG
  51  GCTCCTGCTC ACAGCCTCAC TTCTAACCTT CTGGAACCCG CCCACCACTG
 101  CCAAGCTCAC TATTGAATCC ACGCCGTTCA ATGTCGCAGA GGGGAAGGAG
 151  GTGCTTCTAC TTGTCCACAA TCTGCCCCAG CATCTTTTTG GCTACAGCTG
 201  GTACAAAGGT GAAAGAGTGG ATGGCAACCG TCAAATTATA GGATATGTAA
 251  TAGGAACTCA ACAAGCTACC CCAGGGCCCG CATACAGTGG TCGAGAGATA
 301  ATATACCCCA ATGCATCCCT GCTGATCCAG AACATCATCC AGAATGACAC
 351  AGGATTCTAC ACCCTACACG TCATAAAGTC AGATCTTGTG AATGAAGAAG
 401  CAACTGGCCA GTTCCGGGTA TACCCGGAGC TGCCCAAGCC CTCCATCTCC
 451  AGCAACAACT CCAAACCCGT GGAGGACAAG GATGCTGTGG CCTTCACCTG
 501  TGAACCTGAG ACTCAGGACG CAACCTACCT GTGGTGGGTA AACAATCAGA
 551  GCCTCCCGGT CAGTCCCAGG CTGCAGCTGT CCAATGGCAA CAGGACCCTC
 601  ACTCTATTCA ATGTCACAAG AAATGACACA GCAAGCTACA AATGTGAAAC
 651  CCAGAACCCA GTGAGTGCCA GGCGCAGTGA TTCAGTCATC CTGAATGTCC
 701  TCTATGGCCC GGATGCCCCC ACCATTTCCC CTCTAAACAC ATCTTACAGA
 751  TCAGGGGAAA ATCTGAACCT CTCCTGCCAC GCAGCCTCTA ACCCACCTGC
 801  ACAGTACTCT TGGTTTGTCA ATGGGACTTT CCAGCAATCC ACCCAAGAGC
 851  TCTTTATCCC CAACATCACT GTGAATAATA GTGGATCCTA TACGTGCCAA
 901  GCCCATAACT CAGACACTGG CCTCAATAGG ACCACAGTCA CGACGATCAC
 951  AGTCTATGCA GAGCCACCCA AACCCTTCAT CACCAGCAAC AACTCCAACC
1001  CCGTGGAGGA TGAGGATGCT GTAGCCTTAA CCTGTGAACC TGAGATTCAG
1151  AACACAACCT ACCTGTGGTG GGTAAATAAT CAGAGCCTCC CGGTCAGTCC
1101  CAGGCTGCAG CTGTCCAATG ACAACAGGAC CCTCACTCTA CTCAGTGTCA
1151  CAAGGAATGA TGTAGGACCC TATGAGTGTG GAATCCAGAA CGAATTAAGT
1201  GTTGACCACA GCGACCCAGT CATCCTGAAT GTCCTCTATG GCCCAGACGA
1251  CCCCACCATT TCCCCCTCAT ACACCTATTA CCGTCCAGGG GTGAACCTCA
1301  GCCTCTCCTG CCATGCAGCC TCTAACCCAC CTGCACAGTA TTCTTGGCTG
1351  ATTGATGGGA ACATCCAGCA ACACACACAA GAGCTCTTTA TCTCCAACAT
1401  CACTGAGAAG AACAGCGGAC TCTATACCTG CCAGGCCAAT AACTCAGCCA
1451  GTGGCCACAG CAGGACTACA GTCAAGACAA TCACAGTCTC TGCGGAGCTG
1501  CCCAAGCCCT CCATCTCCAG CAACAACTCC AAACCCGTGG AGGACAAGGA
1551  TGCTGTGGCC TTCACCTGTG AACCTGAGGC TCAGAACACA ACCTACCTGT
1601  GGTGGGTAAA TGGTCAGAGC CTCCCAGTCA GTCCCAGGCT GCAGCTGTCC
1651  AATGGCAACA GGACCCTCAC TCTATTCAAT GTCACAAGAA ATGACGCAAG
1701  AGCCTATGTA TGTGGAATCC AGAACTCAGT GAGTGCAAAC CGCAGTGACC
1751  CAGTCACCCT GGATGTCCTC TATGGGCCGG ACACCCCCAT CATTTCCCCC
1801  CCAGACTCGT CTTACCTTTC GGGAGCGAAC CTCAACCTCT CCTGCCACTC
1851  GGCCTCTAAC CCATCCCCGC AGTATTCTTG GCGTATCAAT GGGATACCGC
1901  AGCAACACAC ACAAGTTCTC TTTATCGCCA AAATCACGCC AAATAATAAC
1951  GGGACCTATG CCTGTTTTGT CTCTAACTTG GCTACTGGCC GCAATAATTC
2001  CATAGTCAAG AGCATCACAG TCTCTGCATC TGGAACTCTA GATGCTCCCC
2051  AGTCTATTAC AGAACTATGT TCGGAATATC GCAACACACA AATATATACG
2101  ATAAATGACA AGATACTATC ATATACGGAA TCGATGGCAG GTAAAAGAGA
2151  AATGGTTATC ATTACATTTA AGAGCGGCGC AACATTTCAG GTCGAAGTCC
2201  CGGGCAGTCA ACATATAGAC TCCCAAAAAA AAGCCATTGA AAGGATGAAG
2251  GACACATTAA GAATCACATA TCTGACCGAG ACCAAAATTG ATAAATTATG
2301  TGTATGGAAT AATAAAACCC CCAATTCAAT TGCGGCAATC AGTATGGAAA
      ACTAG (SEQ ID NO:9)
```

TR0073 PV

FIGURE 3B

CEA-LTB Amino Acid Sequence

```
  1   MESPSAPPHR WCIPWQRLLL TASLLTFWNP PTTAKLTIES TPFNVAEGKE
 51   VLLLVHNLPQ HLFGYSWYKG ERVDGNRQII GYVIGTQQAT PGPAYSGREI
101   IYPNASLLIQ NIIQNDTGFY TLHVIKSDLV NEEATGQFRV YPELPKPSIS
151   SNNSKPVEDK DAVAFTCEPE TQDATYLWWV NNQSLPVSPR LQLSNGNRTL
201   TLFNVTRNDT ASYKCETQNP VSARRSDSVI LNVLYGPDAP TISPLNTSYR
251   SGENLNLSCH AASNPPAQYS WFVNGTFQQS TQELFIPNIT VNNSGSYTCQ
301   AHNSDTGLNR TTVTTITVYA EPPKPFITSN NSNPVEDEDA VALTCEPEIQ
351   NTTYLWWVNN QSLPVSPRLQ LSNDNRTLTL LSVTRNDVGP YECGIQNELS
401   VDHSDPVILN VLYGPDDPTI SPSYTYYRPG VNLSLSCHAA SNPPAQYSWL
451   IDGNIQQHTQ ELFISNITEK NSGLYTCQAN NSASGHSRTT VKTITVSAEL
501   PKPSISSNNS KPVEDKDAVA FTCEPEAQNT TYLWWVNGQS LPVSPRLQLS
551   NGNRTLTLFN VTRNDARAYV CGIQNSVSAN RSDPVTLDVL YGPDTPIISP
601   PDSSYLSGAN LNLSCHSASN PSPQYSWRIN GIPQQHTQVL FIAKITPNNN
651   GTYACFVSNL ATGRNNSIVK SITVSASGTL DAPQSITELC SEYRNTQIYT
701   INDKILSYTE SMAGKREMVI ITFKSGATFQ VEVPGSQHID SQKKAIERMK
751   DTLRITYLTE TKIDKLCVWN NKTPNSIAAI SMEN (SEQ ID NO:10)
```

R0073PV

FIGURE 4

CEAopt-LTB Nucleotide Sequence

```
   1  ATGGAGAGCC CCAGCGCCCC CCCCCACCGC TGGTGCATCC CCTGGCAGCG
      CCTGCTGCTG ACCGCCAGCC TGCTGACCTT CTGGAACCCC CCCACCACCG
 101  CCAAGCTGAC CATCGAGAGC ACCCCCTTCA ACGTGGCCGA GGGCAAGGAG
      GTGCTGCTGC TGGTGCACAA CCTGCCCCAG CACCTGTTCG GCTACAGCTG
 201  GTACAAGGGC GAGCGCGTGG ACGGCAACCG CCAGATCATC GGCTACGTGA
      TCGGCACCCA GCAGGCCACC CCCGGCCCCG CCTACAGCGG CCGCGAGATC
 301  ATCTACCCCA ACGCCAGCCT GCTGATCCAG AACATCATCC AGAACGACAC
      CGGCTTCTAC ACCCTGCACG TGATCAAGAG CGACCTGGTG AACGAGGAGG
 401  CCACCGGCCA GTTCCGCGTG TACCCCGAGC TGCCCAAGCC CAGCATCAGC
      AGCAACAACA GCAAGCCCGT GGAGGACAAG GACGCCGTGG CCTTCACCTG
 501  CGAGCCCGAG ACCCAGGACG CCACCTACCT GTGGTGGGTG AACAACCAGA
      GCCTGCCCGT GAGCCCCCGC CTGCAGCTGA GCAACGGCAA CCGCACCCTG
 601  ACCCTGTTCA ACGTGACCCG CAACGACACC GCCAGCTACA AGTGCGAGAC
      CCAGAACCCC GTGAGCGCCC GCCGCAGCGA CAGCGTGATC CTGAACGTGC
 701  TGTACGGCCC CGACGCCCCC ACCATCAGCC CCCTGAACAC CAGCTACCGC
      AGCGGCGAGA ACCTGAACCT GAGCTGCCAC GCCGCCAGCA ACCCCCCCGC
 801  CCAGTACAGC TGGTTCGTGA ACGGCACCTT CCAGCAGAGC ACCCAGGAGC
      TGTTCATCCC CAACATCACC GTGAACAACA GCGGCAGCTA CACCTGCCAG
 901  GCCCACAACA GCGACACCGG CCTGAACCGC ACCACCGTGA CCACCATCAC
      CGTGTACGCC GAGCCCCCCA AGCCCTTCAT CACCAGCAAC AACAGCAACC
1001  CCGTGGAGGA CGAGGACGCC GTGGCCCTGA CCTGCGAGCC CGAGATCCAG
      AACACCACCT ACCTGTGGTG GGTGAACAAC CAGAGCCTGC CCGTGAGCCC
1101  CCGCCTGCAG CTGAGCAACG ACAACCGCAC CCTGACCCTG CTGAGCGTGA
      CCCGCAACGA CGTGGGCCCC TACGAGTGCG GCATCCAGAA CGAGCTGAGC
1201  GTGGACCACA GCGACCCCGT GATCCTGAAC GTGCTGTACG GCCCCGACGA
      CCCCACCATC AGCCCCAGCT ACACCTACTA CCGCCCCGGC GTGAACCTGA
1301  GCCTGAGCTG CCACGCCGCC AGCAACCCCC CCGCCCAGTA CAGCTGGCTG
      ATCGACGGCA ACATCCAGCA GCACACCCAG GAGCTGTTCA TCAGCAACAT
1401  CACCGAGAAG AACAGCGGCC TGTACACCTG CCAGGCCAAC AACAGCGCCA
      GCGGCCACAG CCGCACCACC GTGAAGACCA TCACCGTGAG CGCCGAGCTG
1501  CCCAAGCCCA GCATCAGCAG CAACAACAGC AAGCCCGTGG AGGACAAGGA
      CGCCGTGGCC TTCACCTGCG AGCCCGAGGC CCAGAACACC ACCTACCTGT
1601  GGTGGGTGAA CGGCCAGAGC CTGCCCGTGA GCCCCCGCCT GCAGCTGAGC
      AACGGCAACC GCACCCTGAC CCTGTTCAAC GTGACCCGCA ACGACGCCCG
1701  CGCCTACGTG TGCGGCATCC AGAACAGCGT GAGCGCCAAC CGCAGCGACC
      CCGTGACCCT GGACGTGCTG TACGGCCCCG ACACCCCCAT CATCAGCCCC
1801  CCCGACAGCA GCTACCTGAG CGGCGCCAAC CTGAACCTGA GCTGCCACAG
      CGCCAGCAAC CCCAGCCCCC AGTACAGCTG GCGCATCAAC GGCATCCCCC
1901  AGCAGCACAC CCAGGTGCTG TTCATCGCCA AGATCACCCC CAACAACAAC
      GGCACCTACG CCTGCTTCGT GAGCAACCTG GCCACCGGCC GCAACAACAG
2001  CATCGTGAAG AGCATCACCG TGAGCGCCAG CGGCACCTCT AGAGCTCCCC
      AGACTATTAC AGAACTATGT TCGGAATATC GCAACACACA AATATATACG
2101  ATAAATGACA AGATACTATC ATATACGGAA TCGATGGCAG GCAAAAGAGA
      AATGGTTATC ATTACATTTA AGAGCGGCGA AACATTTCAG GTCGAAGTCC
2201  CGGGCAGTCA ACATATAGAC TCCCAGAAAA AAGCCATTGA AAGGATGAAG
      GACACATTAA GAATCACATA TCTGACCGAG ACCAAAATTG ATAAATTATG
2301  TGTATGGAAT AATAAAACCC CCAATTCAAT TGCGGCAATC AGTATGGAAA
      ACTAG (SEQ ID NO:11)
```

R0073PV

FIGURE 5A

hCEA-LTBopt Coding Sequence

```
   1  ATGGAGAGCC CCAGCGCCCC CCCCCACCGC TGGTGCATCC CCTGGCAGCG
      CCTGCTGCTG ACCGCCAGCC TGCTGACCTT CTGGAACCCC CCCACCACCG
 101  CCAAGCTGAC CATCGAGAGC ACCCCCTTCA ACGTGGCCGA GGGCAAGGAG
      GTGCTGCTGC TGGTGCACAA CCTGCCCCAG CACCTGTTCG GCTACAGCTG
 201  GTACAAGGGC GAGCGCGTGG ACGGCAACCG CCAGATCATC GGCTACGTGA
      TCGGCACCCA GCAGGCCACC CCCGGCCCCG CCTACAGCGG CCGCGAGATC
 301  ATCTACCCCA ACGCCAGCCT GCTGATCCAG AACATCATCC AGAACGACAC
      CGGCTTCTAC ACCCTGCACG TGATCAAGAG CGACCTGGTG AACGAGGAGG
 401  CCACCGGCCA GTTCCGCGTG TACCCCGAGC TGCCCAAGCC CAGCATCAGC
      AGCAACAACA GCAAGCCCGT GGAGGACAAG GACGCCGTGG CCTTCACCTG
 501  CGAGCCCGAG ACCCAGGACG CCACCTACCT GTGGTGGGTG AACAACCAGA
      GCCTGCCCGT GAGCCCCCGC CTGCAGCTGA GCAACGGCAA CCGCACCCTG
 601  ACCCTGTTCA ACGTGACCCG CAACGACACC GCCAGCTACA AGTGCGAGAC
      CCAGAACCCC GTGAGCGCCC GCCGCAGCGA CAGCGTGATC CTGAACGTGC
 701  TGTACGGCCC CGACGCCCCC ACCATCAGCC CCCTGAACAC CAGCTACCGC
      AGCGGCGAGA ACCTGAACCT GAGCTGCCAC GCCGCCAGCA ACCCCCCCGC
 801  CCAGTACAGC TGGTTCGTGA ACGGCACCTT CCAGCAGAGC ACCCAGGAGC
      TGTTCATCCC CAACATCACC GTGAACAACA GCGGCAGCTA CACCTGCCAG
 901  GCCCACAACA GCGACACCGG CCTGAACCGC ACCACCGTGA CCACCATCAC
      CGTGTACGCC GAGCCCCCCA AGCCCTTCAT CACCAGCAAC AACAGCAACC
1001  CCGTGGAGGA CGAGGACGCC GTGGCCCTGA CCTGCGAGCC CGAGATCCAG
      AACACCACCT ACCTGTGGTG GGTGAACAAC CAGAGCCTGC CCGTGAGCCC
1101  CCGCCTGCAG CTGAGCAACG ACAACCGCAC CCTGACCCTG CTGAGCGTGA
      CCCGCAACGA CGTGGGCCCC TACGAGTGCG GCATCCAGAA CGAGCTGAGC
1201  GTGGACCACA GCGACCCCGT GATCCTGAAC GTGCTGTACG GCCCCGACGA
      CCCCACCATC AGCCCCAGCT ACACCTACTA CCGCCCCGGC GTGAACCTGA
1301  GCCTGAGCTG CCACGCCGCC AGCAACCCCC CCGCCCAGTA CAGCTGGCTG
      ATCGACGGCA ACATCCAGCA GCACACCCAG GAGCTGTTCA TCAGCAACAT
1401  CACCGAGAAG AACAGCGGCC TGTACACCTG CCAGGCCAAC AACAGCGCCA
      GCGGCCACAG CCGCACCACC GTGAAGACCA TCACCGTGAG CGCCGAGCTG
1501  CCCAAGCCCA GCATCAGCAG CAACAACAGC AAGCCCGTGG AGGACAAGGA
      CGCCGTGGCC TTCACCTGCG AGCCCGAGGC CCAGAACACC ACCTACCTGT
1601  GGTGGGTGAA CGGCCAGAGC CTGCCCGTGA GCCCCCGCCT GCAGCTGAGC
      AACGGCAACC GCACCCTGAC CCTGTTCAAC GTGACCCGCA ACGACGCCCG
1701  CGCCTACGTG TGCGGCATCC AGAACAGCGT GAGCGCCAAC CGCAGCGACC
      CCGTGACCCT GGACGTGCTG TACGGCCCCG ACACCCCCAT CATCAGCCCC
1801  CCCGACAGCA GCTACCTGAG CGGCGCCAAC CTGAACCTGA GCTGCCACAG
      CGCCAGCAAC CCCAGCCCCC AGTACAGCTG GCGCATCAAC GGCATCCCCC
1901  AGCAGCACAC CCAGGTGCTG TTCATCGCCA AGATCACCCC CAACAACAAC
      GGCACCTACG CCTGCTTCGT GAGCAACCTG GCCACCGGCC GCAACAACAG
2001  CATCGTGAAG AGCATCACCG TGAGCGCCAG CGGCACCTCT AGAGCCCCCC
      AGAGCATCAC CGAGCTGTGC AGCGAGTACC GGAACACCCA GATCTACACC
2101  ATCAACGACA AGATCCTGAG CTACACCGAG AGCATGGCCG GCAAGAGGGA
      GATGGTGATC ATCACCTTCA AGAGCGGCGC CACCTTCCAG GTGGAGGTGC
2201  CCGGCAGCCA GCACATCGAC AGCCAGAAGA AGGCCATCGA GCGGATGAAG
      GACACCCTGC GGATCACCTA CCTCACCGAG ACCAAGATCG ACAAGCTGTG
2301  CGTGTGGAAC AACAAGACCC CCAACAGCAT CGCCGCCATC AGCATGGAGA
      ATTGATAA (SEQ ID NO:12)
```

R0073PV

FIGURE 5B

hCEA-LTB Amino Acid Sequence

```
  1   MESPSAPPHR WCIPWQRLLL TASLLTFWNP PTTAKLTIES TPFNVAEGKE
 51   VLLLVHNLPQ HLFGYSWYKG ERVDGNRQII GYVIGTQQAT PGPAYSGREI
101   IYPNASLLIQ NIIQNDTGFY TLHVIKSDLV NEEATGQFRV YPELPKPSIS
151   SNNSKPVEDK DAVAFTCEPE TQDATYLWWV NNQSLPVSPR LQLSNGNRTL
201   TLFNVTRNDT ASYKCETQNP VSARRSDSVI LNVLYGPDAP TISPLNTSYR
251   SGENLNLSCH AASNPPAQYS WFVNGTFQQS TQELFIPNIT VNNSGSYTCQ
301   AHNSDTGLNR TTVTTITVYA EPPKPFITSN NSNPVEDEDA VALTCEPEIQ
351   NTTYLWWVNN QSLPVSPRLQ LSNDNRTLTL LSVTRNDVGP YECGIQNELS
401   VDHSDPVILN VLYGPDDPTI SPSYTYYRPG VNLSLSCHAA SNPPAQYSWL
451   IDGNIQQHTQ ELFISNITEK NSGLYTCQAN NSASGHSRTT VKTITVSAEL
501   PKPSISSNNS KPVEDKDAVA FTCEPEAQNT TYLWWVNGQS LPVSPRLQLS
551   NGNRTLTLFN VTRNDARAYV CGIQNSVSAN RSDPVTLDVL YGPDTPIISP
601   PDSSYLSGAN LNLSCHSASN PSPQYSWRIN GIPQQHTQVL FIAKITPNNN
651   GTYACFVSNL ATGRNNSIVK SITVSASGTS RAPQSITELC SEYRNTQIYT
701   INDKILSYTE SMAGKREMVI ITFKSGATFQ VEVPGSQHID SQKKAIERMK
751   DTLRITYLTE TKIDKLCVWN NKTPNSIAAI SMEN (SEQ ID NO:13)
```

R0073PV

FIGURE 6A

Rhesus CEAopt-LTBopt Coding Sequence

ATGGGCAGCC CCAGCGCCCC CCTGCACCGC TGGTGCATCC CCTGGCAGAC CCTGCTGCTG ACCGCCAGCC
TGCTGACCTT CTGGAACCCC CCCACCACCG CCCAGCTGAC CATCGAGAGC CGCCCCTTCA ACGTGGCCGA
GGGCAAGGAG GTGCTGCTGC TGGCCCACAA CGTGAGCCAG AACCTGTTCG GCTACATCTG GTACAAGGGC
GAGCGCGTGG ACGCCAGCCG CCGCATCGGC AGCTGCGTGA TCCGCACCCA GCAGATCACC CCCGGCCCCG
CCCACAGCGG CCGCGAGACC ATCGACTTCA ACGCCAGCCT GCTGATCCAC AACGTGACCC AGAGCGACAC
CGGCAGCTAC ACCATCCAGG TGATCAAGGA GGACCTGGTG AACGAGGAGG CCACCGGCCA GTTCCGCGTG
TACCCCGAGC TGCCCAAGCC CTACATCAGC AGCAACAACA GCAACCCCGT GGAGGACAAG GACGCCGTGG
CCCTGACCTG CGAGCCCGAG ACCCAGGACA CCACCTACCT GTGGTGGGTG AACAACCAGA GCCTGCCCGT
GAGCCCCCGC CTGGAGCTGA GCAGCGACAA CCGCACCCTG ACCGTGTTCA ACATCCCCCG CAACGACACC
ACCAGCTACA AGTGCGAGAC CCAGAACCCC GTGAGCGTGC GCCGCAGCGA CCCCGTGACC CTGAACGTGC
TGTACGGCCC CGACGCCCCC ACCATCAGCC CCCTGAACAC CCCCTACCGC GCCGGCGAGA ACCTGAACCT
GACCTGCCAC GCCGCCAGCA ACCCCACCGC CCAGTACTTC TGGTTCGTGA ACGGCACCTT CCAGCAGAGC
ACCCAGGAGC TGTTCATCCC CAACATCACC GTGAACAACA GCGGCAGCTA CATGTGCCAG GCCCACAACA
GCGCCACCGG CCTGAACCGC ACCACCGTGA CCGCCATCAC CGTGTACGCC GAGCTGCCCA AGCCCTACAT
CACCAGCAAC AACAGCAACC CCATCGAGGA CAAGGACGCC GTGACCCTGA CCTGCGAGCC CGAGACCCAG
GACACCACCT ACCTGTGGTG GGTGAACAAC CAGAGCCTGA GCGTGAGCAG CCGCCTGGAG CTGAGCAACG
ACAACCGCAC CCTGACCGTG TTCAACATCC CCCGCAACGA CACCACCTTC TACGAGTGCG AGACCCAGAA
CCCCGTGAGC GTGCGCCGCA GCGACCCCGT GACCCTGAAC GTGCTGTACG GCCCCGACGC CCCCACCATC
AGCCCCCTGA ACACCCCCTA CCGCGCCGGC GAGAACCTGA ACCTGAGCTG CCACGCCGCC AGCAACCCCG
CCGCCCAGTA CAGCTGGTTC GTGAACGGCA CCTTCCAGCA GAGCACCCAG GAGCTGTTCA TCCCCAACAT
CACCGTGAAC AACAGCGGCA GCTACATGTG CCAGGCCCAC AACAGCGCCA CCGGCCTGAA CCGCACCACC
GTGACCGCCA TCACCGTGTA CGTGGAGCTG CCCAAGCCCT ACATCAGCAG CAACAACAGC AACCCCATCG
AGGACAAGGA CGCCGTGACC CTGACCTGCG AGCCCGTGGC CGAGAACACC ACCTACCTGT GGTGGGTGAA
CAACCAGAGC CTGAGCGTGA GCCCCCGCCT GCAGCTGAGC AACGGCAACC GCATCCTGAC CCTGCTGAGC
GTGACCCGCA ACGACACCGG CCCCTACGAG TGCGGCATCC AGAACAGCGA GAGCGCCAAG CGCAGCGACC
CCGTGACCCT GAACGTGACC TACGGCCCCG ACACCCCCAT CATCAGCCCC CCCGACCTGA GCTACCGCAG
CGGCGCCAAC CTGAACCTGA GCTGCCACAG CGACAGCAAC CCCAGCCCCC AGTACAGCTG GCTGATCAAC
GGCACCCTGC GCCAGCACAC CCAGGTGCTG TTCATCAGCA AGATCACCAG CAACAACAGC GGCGCCTACG
CCTGCTTCGT GAGCAACCTG GCCACCGGCC GCAACAACAG CATCGTGAAG AACATCAGCG TGAGCAGCGG
CGACAGCTCT AGA**GCCCCCC AGAGCATCAC CGAGCTGTGC AGCGAGTACC GGAACACCCA GATCTACACC
ATCAACGACA AGATCCTGAG CTACACCGAG AGCATGGCCG GCAAGAGGGA GATGGTGATC ATCACCTTCA
AGAGCGGCGC CACCTTCCAG GTGGAGGTGC CCGGCAGCCA GCACATCGAC AGCCAGAAGA AGGCCATCGA
GCGGATGAAG GACACCCTGC GGATCACCTA CCTCACCGAG ACCAAGATCG ACAAGCTGTG CGTGTGGAAC
AACAAGACCC CCAACAGCAT CGCCGCCATC AGCATGGAGA ATTGATAA** (SEQ ID NO:14)

R0073PV

FIGURE 6B

RhCEAopt-LTBopt Amino Acid Sequence

```
  1   MGSPSAPLHR WCIPWQTLLL TASLLTFWNP PTTAQLTIES RPFNVAEGKE
 51   VLLLAHNVSQ NLFGYIWYKG ERVDASRRIG SCVIRTQQIT PGPAHSGRET
101   IDFNASLLIH NVTQSDTGSY TIQVIKEDLV NEEATGQFRV YPELPKPYIS
151   SNNSNPVEDK DAVALTCEPE TQDTTYLWWV NNQSLPVSPR LELSSDNRTL
201   TVFNIPRNDT TSYKCETQNP VSVRRSDPVT LNVLYGPDAP TISPLNTPYR
251   AGENLNLTCH AASNPTAQYF WFVNGTFQQS TQELFIPNIT VNNSGSYMCQ
301   AHNSATGLNR TTVTAITVYA ELPKPYITSN NSNPIEDKDA VTLTCEPETQ
351   DTTYLWWVNN QSLSVSSRLE LSNDNRTLTV FNIPRNDTTF YECETQNPVS
401   VRRSDPVTLN VLYGPDAPTI SPLNTPYRAG ENLNLSCHAA SNPAAQYSWF
451   VNGTFQQSTQ ELFIPNITVN NSGSYMCQAH NSATGLNRTT VTAITVYVEL
501   PKPYISSNNS NPIEDKDAVT LTCEPVAENT TYLWWVNNQS LSVSPRLQLS
551   NGNRILTLLS VTRNDTGPYE CGIQNSESAK RSDPVTLNVT YGPDTPIISP
601   PDLSYRSGAN LNLSCHSDSN PSPQYSWLIN GTLRQHTQVL FISKITSNNS
651   GAYACFVSNL ATGRNNSIVK NISVSSGDSS RAPQSITELC SEYRNTQIYT
701   INDKILSYTE SMAGKREMVI ITFKSGATFQ VEVPGSQHID SQKKAIERMK
751   DTLRITYLTE TKIDKLCVWN NKTPNSIAAI SMEN (SEQ ID NO:15)
```

R0073PV

FIGURE 7A. Nucleotide sequence of first rhesus CEA

```
   1  ATGGGGTCTC CCTCAGCCCC TCTTCACAGA TGGTGCATCC CCTGGCAGAC
  51  GCTCCTGCTC ACAGCCTCAC TTCTAACCTT CTGGAACCCG CCCACCACTG
 101  CCCAGCTCAC TATTGAATCC AGGCCGTTCA ATGTTGCAGA GGGGAAGGAG
 151  GTTCTTCTAC TTGCCCACAA TGTGTCCCAG AATCTTTTTG GCTACATTTG
 201  GTACAAGGGA GAAAGAGTGG ATGCCAGCCG TCGAATTGGA TCATGTGTAA
 251  TAAGAACTCA ACAAATTACC CCAGGGCCCG CACACAGCGG TCGAGAGACA
 301  ATAGACTTCA ATGCATCCCT GCTGATCCAC AATGTCACCC AGAGTGACAC
 351  AGGATCCTAC ACCATACAAG TCATAAAGGA AGATCTTGTG AATGAAGAAG
 401  CAACTGGCCA GTTCCGGGTA TACCCGGAGC TGCCCAAGCC CTACATCTCC
 451  AGCAACAACT CCAACCCCGT GGAGGACAAG GATGCTGTGG CCTTAACCTG
 501  TGAACCTGAG ACTCAGGACA CAACCTACCT GTGGTGGGTA AACAATCAGA
 551  GCCTCCCGGT CAGTCCCAGG CTGGAGCTGT CCAGTGACAA CAGGACCCTC
 601  ACTGTATTCA ATATTCCAAG AAATGACACA ACATCCTACA AATGTGAAAC
 651  CCAGAACCCA GTGAGTGTCA GACGCAGCGA CCCAGTCACC CTGAACGTCC
 701  TCTATGGCCC GGATGCGCCC ACCATTTCCC CTCTAAACAC ACCTTACAGA
 751  GCAGGGGAAA ATCTGAACCT CACCTGCCAC GCAGCCTCTA ACCCAACTGC
 801  ACAGTACTTT TGGTTTGTCA ATGGGACGTT CCAGCAATCC ACACAAGAGC
 851  TCTTTATACC CAACATCACC GTGAATAATA GCGGATCCTA TATGTGCCAA
 901  GCCCATAACT CAGCCACTGG CCTCAATAGG ACCACAGTCA CGGCGATCAC
 951  AGTCTACGCG GAGCTGCCCA AGCCCTACAT CACCAGCAAC AACTCCAACC
1001  CCATAGAGGA CAAGGATGCT GTGACCTTAA CCTGTGAACC TGAGACTCAG
1051  GACACAACCT ACCTGTGGTG GGTAAACAAT CAGAGCCTCT CGGTCAGTTC
1101  CAGGCTGGAG CTGTCCAATG ACAACAGGAC CCTCACTGTA TTCAATATTC
1151  CAAGAAACGA CACAACGTTC TACGAATGTG AGACCCAGAA CCCAGTGAGT
1201  GTCAGACGCA GCGACCCAGT CACCCTGAAT GTCCTCTATG GCCCGGATGC
1251  GCCCACCATT TCCCCTCTAA ACACACCTTA CAGAGCAGGG GAAAATCTGA
1301  ACCTCTCCTG CCACGCAGCC TCTAACCCAG CTGCACAGTA CTCTTGGTTT
1351  GTCAATGGGA CGTTCCAGCA ATCCACACAA GAGCTCTTTA TACCCAACAT
1401  CACCGTGAAT AATAGCGGAT CCTATATGTG CCAAGCCCAT AACTCAGCCA
1451  CTGGCCTCAA TAGGACCACA GTCACGGCGA TCACAGTCTA TGTGGAGCTG
1501  CCCAAGCCCT ACATCTCCAG CAACAACTCC AACCCCATAG AGGACAAGGA
1551  TGCTGTGACC TTAACCTGTG AACCTGTGGC TGAGAACACA ACCTACCTGT
1601  GGTGGGTAAA CAATCAGAGC CTCTCGGTCA GTCCCAGGCT GCAGCTCTCC
1651  AATGGCAACA GGATCCTCAC TCTACTCAGT GTCACACGGA ATGACACAGG
1701  ACCCTATGAA TGTGGAATCC AGAACTCAGA GAGTGCAAAA CGCAGTGACC
1751  CAGTCACCCT GAATGTCACC TATGGCCCAG ACACCCCCAT CATATCCCCC
1801  CCAGACTTGT CTTACCGTTC GGGAGCAAAC CTCAACCTCT CCTGCCACTC
1851  GGACTCTAAC CCATCCCCGC AGTATTCTTG GCTTATCAAT GGGACACTGC
1901  GGCAACACAC ACAAGTTCTC TTTATCTCCA AAATCACATC AAACAATAGC
1951  GGGGCCTATG CCTGTTTTGT CTCTAACTTG GCTACCGGTC GCAATAACTC
2001  CATAGTCAAG AACATCTCAG TCTCCTCTGG CGATTCAGCA CCTGGAAGTT
2051  CTGGTCTCTC AGCTAGGGCT ACTGTCGGCA TCATAATTGG AATGCTGGTT
2101  GGGGTTGCTC TGATGTAG (SEQ ID NO:16)
```

P0073PV

FIGURE 7B. Nucleotide Sequence of Second Rhesus CEA

```
   1  ATGGGGTCTC CCTCAGCCCC TCTTCACAGA TGGTGCATCC CCTGGCAGAC
  51  GCTCCTGCTC ACAGCCTCAC TTCTAACCTT CTGGAACCCG CCCACCACTG
 101  CCCAGCTCAC TATTGAATCC AGGCCGTTCA ATGTTGCAGA GGGGAAGGAG
 151  GTTCTTCTAC TTGCCCACAA TGTGTCCCAG AATCTTTTTG GCTACATTTG
 201  GTACAAGGGA GAAAGAGTGG ATGCCAGCCG TCGAATTGGA TCATGTGTAA
 251  TAAGAACTCA ACAAATTACC CCAGGGCCCG CACACAGCGG TCGAGAGACA
 301  ATAGACTTCA ATGCATCCCT GCTGATCCAC AATGTCACCC AGAGTGACAC
 351  AGGATCCTAC ACCATACAAG TCATAAAGGA AGATCTTGTG AATGAAGAAG
 401  CAACTGGCCA GTTCCGGGTA TACCCGGAGC TGCCCAAGCC CTACATCTCC
 451  AGCAACAACT CCAACCCCGT GGAGGACAAG GATGCTGTGG CCTTAACCTG
 501  TGAACCTGAG ACTCAGGACA CAACCTACCT GTGGTGGGTA AACAATCAGA
 551  GCCTCCCGGT CAGTCCCAGG CTGGAGCTGT CCAGTGACAA CAGGACCCTC
 601  ACTGTATTCA ATATTCCAAG AAATGACACA ACATCCTACA AATGTGAAAC
 651  CCAGAACCCA GTGAGTGTCA GACGCAGCGA CCCAGTCACC CTGAACGTCC
 701  TCTATGGCCC GGATGCGCCC ACCATTTCCC CTCTAAACAC ACCTTACAGA
 751  GCAGGGGAAA ATCTGAACCT CACCTGCCAC GCAGCCTCTA ACCCAACTGC
 801  ACAGTACTTT TGGTTTGTCA ATGGGACGTT CCAGCAATCC ACACAAGAGC
 851  TCTTTATACC CAACATCACC GTGAATAATA GCGGATCCTA TATGTGCCAA
 901  GCCCATAACT CAGCCACTGG CCTCAATAGG ACCACAGTCA CGGCGATCAC
 951  AGTCTACGCG GAGCTGCCCA AGCCCTACAT CACCAGCAAC AACTCCAACC
1001  CCATAGAGGA CAAGGATGCT GTGACCTTAA CCTGTGAACC TGAGACTCAG
1051  GACACAACCT ACCTGTGGTG GGTAAACAAT CAGAGCCTCT CGGTCAGTTC
1101  CAGGCTGGAG CTGTCCAATG ACAACAGGAC CCTCACTGTA TTCAATATTC
1151  CAAGAAACGA CACAACGTTC TACGAATGTG AGACCCAGAA CCCAGTGAGT
1201  GTCAGACGCA GCGACCCAGT CACCCTGAAT GTCCTCTATG GCCCGGATGC
1251  GCCCACCATT TCCCCTCTAA ACACACCTTA CAGAGCAGGG GAAAATCTGA
1301  ACCTCTCCTG CCACGCAGCC TCTAACCCAG CTGCACAGTA CTTTTGGTTT
1351  GTCAATGGGA CGTTCCAGCA ATCCACACAA GAGCTCTTTA TACCCAACAT
1401  CACCGTGAAT AATAGCGGAT CCTATATGTG CCAAGCCCAT AACTCAGCCA
1451  CTGGCCTCAA TAGGACCACA GTCACGGCGA TCACAGTCTA TGTGGAGCTG
1501  CCCAAGCCCT ACATCTCCAG CAACAACTCC AACCCCATAG AGGACAAGGA
1551  TGCTGTGACC TTAACCTGTG AACCTGTGGC TGAGAACACA ACCTACCTGT
1601  GGTGGGTAAA CAATCAGAGC CTCTCGGTCA GTCCCAGGCT GCAGCTCTCC
1651  AATGGCAACA GGATCCTCAC TCTACTCAGT GTCACACGGA ATGACACAGG
1701  ACCCTATGAA TGTGGAATCC AGAACTCAGA GAGTGCAAAA CGCAGTGACC
1751  CAGTCACCCT GAATGTCACC TATGGCCCAG ACACCCCCAT CATATCCCCC
1801  CCAGACTTGT CTTACCGTTC GGGAGCAAAC CTCAACCTCT CCTGCCACTC
1851  GGACTCTAAC CCATCCCCGC AGTATTCTTG GCTTATCAAT GGGACACTGC
1901  GGCAACACAC ACAAGTTCTC TTTATCTCCA AAATCACATC AAACAATAAC
1951  GGGGCCTATG CCTGTTTTGT CTCTAACTTG GCTACCGGTC GCAATAACTC
2001  CATAGTCAAG AACATCTCAG TCTCCTCTGG CGATTCAGCA CCTGGAAGTT
2051  CTGGTCTCTC AGCTAGGGCT ACTGTCGGCA TCATAATTGG AATGCTGGTT
2101  GGGGTTGCTC TGATGTAG (SEQ ID NO:17)
```

FIGURE 7C. Amino Acid Sequence of First Rhesus CEA Protein

```
  1     MGSPSAPLHR WCIPWQTLLL TASLLTFWNP PTTAQLTIES RPFNVAEGKE
 51     VLLLAHNVSQ NLFGYIWYKG ERVDASRRIG SCVIRTQQIT PGPAHSGRET
101     IDFNASLLIH NVTQSDTGSY TIQVIKEDLV NEEATGQFRV YPELPKPYIS
151     SNNSNPVEDK DAVALTCEPE TQDTTYLWWV NNQSLPVSPR LELSSDNRTL
201     TVFNIPRNDT TSYKCETQNP VSVRRSDPVT LNVLYGPDAP TISPLNTPYR
251     AGENLNLTCH AASNPTAQYF WFVNGTFQQS TQELFIPNIT VNNSGSYMCQ
301     AHNSATGLNR TTVTAITVYA ELPKPYITSN NSNPIEDKDA VTLTCEPETQ
351     DTTYLWWVNN QSLSVSSRLE LSNDNRTLTV FNIPRNDTTF YECETQNPVS
401     VRRSDPVTLN VLYGPDAPTI SPLNTPYRAG ENLNLSCHAA SNPAAQYSWF
451     VNGTFQQSTQ ELFIPNITVN NSGSYMCQAH NSATGLNRTT VTAITVYVEL
501     PKPYISSNNS NPIEDKDAVT LTCEPVAENT TYLWWVNNQS LSVSPRLQLS
551     NGNRILTLLS VTRNDTGPYE CGIQNSESAK RSDPVTLNVT YGPDTPIISP
601     PDLSYRSGAN LNLSCHSDSN PSPQYSWLIN GTLRQHTQVL FISKITSNNS
651     GAYACFVSNL ATGRNNSIVK NISVSSGDSA PGSSGLSARA TVGIIIGMLV
701     GVALM (SEQ ID NO:18.)
```

FIGURE 7D. Amino Acid Sequence of Second Rhesus CEA Protein

```
  1     MGSPSAPLHR WCIPWQTLLL TASLLTFWNP PTTAQLTIES RPFNVAEGKE
 51     VLLLAHNVSQ NLFGYIWYKG ERVDASRRIG SCVIRTQQIT PGPAHSGRET
101     IDFNASLLIH NVTQSDTGSY TIQVIKEDLV NEEATGQFRV YPELPKPYIS
151     SNNSNPVEDK DAVALTCEPE TQDTTYLWWV NNQSLPVSPR LELSSDNRTL
201     TVFNIPRNDT TSYKCETQNP VSVRRSDPVT LNVLYGPDAP TISPLNTPYR
251     AGENLNLTCH AASNPTAQYF WFVNGTFQQS TQELFIPNIT VNNSGSYMCQ
301     AHNSATGLNR TTVTAITVYA ELPKPYITSN NSNPIEDKDA VTLTCEPETQ
351     DTTYLWWVNN QSLSVSSRLE LSNDNRTLTV FNIPRNDTTF YECETQNPVS
401     VRRSDPVTLN VLYGPDAPTI SPLNTPYRAG ENLNLSCHAA SNPAAQYFWF
451     VNGTFQQSTQ ELFIPNITVN NSGSYMCQAH NSATGLNRTT VTAITVYVEL
501     PKPYISSNNS NPIEDKDAVT LTCEPVAENT TYLWWVNNQS LSVSPRLQLS
551     NGNRILTLLS VTRNDTGPYE CGIQNSESAK RSDPVTLNVT YGPDTPIISP
601     PDLSYRSGAN LNLSCHSDSN PSPQYSWLIN GTLRQHTQVL FISKITSNNN
651     GAYACFVSNL ATGRNNSIVK NISVSSGDSA PGSSGLSARA TVGIIIGMLV
701     GVALM (SEQ ID NO:19)
```

R0073 PV

FIGURE 7E. Amino Acid Sequence of Human CEA Protein

```
  1   MESPSAPPHR WCIPWQRLLL TASLLTFWNP PTTAKLTIES TPFNVAEGKE
 51   VLLLVHNLPQ HLFGYSWYKG ERVDGNRQII GYVIGTQQAT PGPAYSGREI
101   IYPNASLLIQ NIIQNDTGFY TLHVIKSDLV NEEATGQFRV YPELPKPSIS
151   SNNSKPVEDK DAVAFTCEPE TQDATYLWWV NNQSLPVSPR LQLSNGNRTL
201   TLFNVTRNDT ASYKCETQNP VSARRSDSVI LNVLYGPDAP TISPLNTSYR
251   SGENLNLSCH AASNPPAQYS WFVNGTFQQS TQELFIPNIT VNNSGSYTCQ
301   AHNSDTGLNR TTVTTITVYA EPPKPFITSN NSNPVEDEDA VALTCEPEIQ
351   NTTYLWWVNN QSLPVSPRLQ LSNDNRTLTL LSVTRNDVGP YECGIQNELS
401   VDHSDPVILN VLYGPDDPTI SPSYTYYRPG VNLSLSCHAA SNPPAQYSWL
451   IDGNIQQHTQ ELFISNITEK NSGLYTCQAN NSASGHSRTT VKTITVSAEL
501   PKPSISSNNS KPVEDKDAVA FTCEPEAQNT TYLWWVNGQS LPVSPRLQLS
551   NGNRTLTLFN VTRNDARAYV CGIQNSVSAN RSDPVTLDVL YGPDTPIISP
601   PDSSYLSGAN LNLSCHSASN PSPQYSWRIN GIPQQHTQVL FIAKITPNNN
651   GTYACFVSNL ATGRNNSIVK SITVSASGTS PGLSAGATVG IMIGVLVGVA
701   LI (SEQ ID NO:20)
```

FIGURE 8

A



B



FIGURE 9



Ad vectors
HeLa cells

R0073PV

FIGURE 10A



2007BPV

FIGURE 10B



R0073PV

FIGURE 11



R0073PV

FIGURE 12



TR0073PV

FIGURE 13



20073PV

FIGURE 14



FIGURE 15



5 wkly inj.
50 µg/inj
CEA-tg mice
N= 9

△ geom mean



FIGURE 16



FIGURE 17